TW201625662A - 妥布賴森(tubulysin)衍生物 - Google Patents
妥布賴森(tubulysin)衍生物 Download PDFInfo
- Publication number
- TW201625662A TW201625662A TW104111700A TW104111700A TW201625662A TW 201625662 A TW201625662 A TW 201625662A TW 104111700 A TW104111700 A TW 104111700A TW 104111700 A TW104111700 A TW 104111700A TW 201625662 A TW201625662 A TW 201625662A
- Authority
- TW
- Taiwan
- Prior art keywords
- cancer
- compound
- etoac
- antibody
- formula
- Prior art date
Links
- DLKUYSQUHXBYPB-NSSHGSRYSA-N (2s,4r)-4-[[2-[(1r,3r)-1-acetyloxy-4-methyl-3-[3-methylbutanoyloxymethyl-[(2s,3s)-3-methyl-2-[[(2r)-1-methylpiperidine-2-carbonyl]amino]pentanoyl]amino]pentyl]-1,3-thiazole-4-carbonyl]amino]-2-methyl-5-(4-methylphenyl)pentanoic acid Chemical class N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(C)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C DLKUYSQUHXBYPB-NSSHGSRYSA-N 0.000 title abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 53
- 150000001875 compounds Chemical class 0.000 claims description 113
- 201000011510 cancer Diseases 0.000 claims description 50
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 39
- 239000000611 antibody drug conjugate Substances 0.000 claims description 37
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 7
- 206010038389 Renal cancer Diseases 0.000 claims description 7
- 201000010982 kidney cancer Diseases 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 4
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 210000004392 genitalia Anatomy 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 208000030427 mucinous ovarian cancer Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 201000000053 blastoma Diseases 0.000 claims description 2
- 229960005395 cetuximab Drugs 0.000 claims description 2
- 201000008184 embryoma Diseases 0.000 claims description 2
- 229960000578 gemtuzumab Drugs 0.000 claims description 2
- 229960001972 panitumumab Drugs 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 210000004498 neuroglial cell Anatomy 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 28
- 238000011282 treatment Methods 0.000 abstract description 23
- 229940127089 cytotoxic agent Drugs 0.000 abstract description 12
- 230000001225 therapeutic effect Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 10
- 239000002254 cytotoxic agent Substances 0.000 abstract description 5
- 231100000599 cytotoxic agent Toxicity 0.000 abstract description 5
- 238000002512 chemotherapy Methods 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 323
- 235000019439 ethyl acetate Nutrition 0.000 description 162
- 239000000243 solution Substances 0.000 description 114
- 239000011347 resin Substances 0.000 description 113
- 229920005989 resin Polymers 0.000 description 113
- 239000000203 mixture Substances 0.000 description 107
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 106
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 102
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
- 238000006243 chemical reaction Methods 0.000 description 69
- 238000005481 NMR spectroscopy Methods 0.000 description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
- 239000011541 reaction mixture Substances 0.000 description 37
- 239000012267 brine Substances 0.000 description 36
- 239000011734 sodium Substances 0.000 description 36
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 36
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- 229920006395 saturated elastomer Polymers 0.000 description 25
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 23
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 238000003818 flash chromatography Methods 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- 239000000725 suspension Substances 0.000 description 21
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 239000013058 crude material Substances 0.000 description 19
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- -1 hormone therapy Substances 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- 238000003756 stirring Methods 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 14
- 229940124597 therapeutic agent Drugs 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 239000007864 aqueous solution Substances 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 12
- 102000018358 immunoglobulin Human genes 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 238000004809 thin layer chromatography Methods 0.000 description 12
- 239000007821 HATU Substances 0.000 description 11
- 238000009739 binding Methods 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000013078 crystal Substances 0.000 description 10
- 238000004007 reversed phase HPLC Methods 0.000 description 10
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000000562 conjugate Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 5
- OVBFMEVBMNZIBR-UHFFFAOYSA-N -2-Methylpentanoic acid Natural products CCCC(C)C(O)=O OVBFMEVBMNZIBR-UHFFFAOYSA-N 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 5
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- HMVYYTRDXNKRBQ-UHFFFAOYSA-N 1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC=N1 HMVYYTRDXNKRBQ-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- WOJKKJKETHYEAC-UHFFFAOYSA-N 6-Maleimidocaproic acid Chemical compound OC(=O)CCCCCN1C(=O)C=CC1=O WOJKKJKETHYEAC-UHFFFAOYSA-N 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229960003901 dacarbazine Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 238000004808 supercritical fluid chromatography Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 3
- 230000004797 therapeutic response Effects 0.000 description 3
- PQQRHWFRZHFGFM-UHFFFAOYSA-N 1,3-thiazole-4-carboxamide Chemical compound NC(=O)C1=CSC=N1 PQQRHWFRZHFGFM-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 2
- PXQMSTLNSHMSJB-UHFFFAOYSA-N 4,4-dimethylcyclohexan-1-one Chemical compound CC1(C)CCC(=O)CC1 PXQMSTLNSHMSJB-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 241001460678 Napo <wasp> Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 239000002038 ethyl acetate fraction Substances 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 150000002374 hemiaminals Chemical class 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 2
- 229960002218 sodium chlorite Drugs 0.000 description 2
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- KQODQNJLJQHFQV-UHFFFAOYSA-N (-)-hemiasterlin Natural products C1=CC=C2C(C(C)(C)C(C(=O)NC(C(=O)N(C)C(C=C(C)C(O)=O)C(C)C)C(C)(C)C)NC)=CN(C)C2=C1 KQODQNJLJQHFQV-UHFFFAOYSA-N 0.000 description 1
- WMSUFWLPZLCIHP-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 9h-fluoren-9-ylmethyl carbonate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)ON1C(=O)CCC1=O WMSUFWLPZLCIHP-UHFFFAOYSA-N 0.000 description 1
- UQHCHLWYGMSPJC-PHDIDXHHSA-N (2r,4r)-4-methylpiperidin-1-ium-2-carboxylate Chemical compound C[C@@H]1CCN[C@@H](C(O)=O)C1 UQHCHLWYGMSPJC-PHDIDXHHSA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 1
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 1
- BBOLKJADNGABCY-WCBMZHEXSA-N (2s,4r)-4-amino-2-methyl-5-(4-nitrophenyl)pentanoic acid Chemical compound OC(=O)[C@@H](C)C[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 BBOLKJADNGABCY-WCBMZHEXSA-N 0.000 description 1
- GLUJNGJDHCTUJY-RXMQYKEDSA-N (3R)-beta-leucine Chemical compound CC(C)[C@H]([NH3+])CC([O-])=O GLUJNGJDHCTUJY-RXMQYKEDSA-N 0.000 description 1
- ULYZWCDMRLCTNS-SECBINFHSA-N (3r)-4-methyl-3-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pentanoic acid Chemical compound OC(=O)C[C@H](C(C)C)N(C)C(=O)OC(C)(C)C ULYZWCDMRLCTNS-SECBINFHSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- KQODQNJLJQHFQV-MKWZWQCGSA-N (e,4s)-4-[[(2s)-3,3-dimethyl-2-[[(2s)-3-methyl-2-(methylamino)-3-(1-methylindol-3-yl)butanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid Chemical compound C1=CC=C2C(C(C)(C)[C@@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)NC)=CN(C)C2=C1 KQODQNJLJQHFQV-MKWZWQCGSA-N 0.000 description 1
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- IANXAXNUNBAWBA-UHFFFAOYSA-N 2,2,3-trimethylundecane Chemical compound CCCCCCCCC(C)C(C)(C)C IANXAXNUNBAWBA-UHFFFAOYSA-N 0.000 description 1
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 1
- ZDUQJTVUWQHXBF-ZIAGYGMSSA-N 2-[(1r,3r)-1-acetyloxy-4-methyl-3-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pentyl]-1,3-thiazole-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N(C)[C@@H](C(C)C)C[C@@H](OC(C)=O)C1=NC(C(O)=O)=CS1 ZDUQJTVUWQHXBF-ZIAGYGMSSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- HXDSPBCJEQJDSB-UHFFFAOYSA-N 2-ethylpiperidin-1-ium-2-carboxylate Chemical compound CCC1(C(O)=O)CCCCN1 HXDSPBCJEQJDSB-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- FTACTAWTKDTQSA-UHFFFAOYSA-N 2-methoxy-2,3,3-trimethylbutane Chemical compound COC(C)(C)C(C)(C)C FTACTAWTKDTQSA-UHFFFAOYSA-N 0.000 description 1
- BDAXXVZMKUJADB-UHFFFAOYSA-N 2-methyl-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCCCC1(C)C(O)=O BDAXXVZMKUJADB-UHFFFAOYSA-N 0.000 description 1
- TTZKHMJRCOJTDF-UHFFFAOYSA-N 3,3-dichloro-5,5-dimethylazepan-2-one Chemical compound CC1(C)CCNC(=O)C(Cl)(Cl)C1 TTZKHMJRCOJTDF-UHFFFAOYSA-N 0.000 description 1
- YKPZVCTXAADWGM-UHFFFAOYSA-N 5-(4-aminophenyl)-2-methylpentanoic acid Chemical compound OC(=O)C(C)CCCC1=CC=C(N)C=C1 YKPZVCTXAADWGM-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
- JQJPBYFTQAANLE-UHFFFAOYSA-N Butyl nitrite Chemical compound CCCCON=O JQJPBYFTQAANLE-UHFFFAOYSA-N 0.000 description 1
- SHZNADSKUZANLF-GXTWGEPZSA-N C(C)(C)(C)OC(=O)N[C@H](C[C@@H](C(=O)OC)C)CC1=CC=C(C=C1)[N+](=O)[O-] Chemical compound C(C)(C)(C)OC(=O)N[C@H](C[C@@H](C(=O)OC)C)CC1=CC=C(C=C1)[N+](=O)[O-] SHZNADSKUZANLF-GXTWGEPZSA-N 0.000 description 1
- JPXNYGSRHUPYTF-CYBMUJFWSA-N C(C1=CC=CC=C1)OC(=O)N1[C@H](CC(CC1)(C)C)C(=O)O Chemical compound C(C1=CC=CC=C1)OC(=O)N1[C@H](CC(CC1)(C)C)C(=O)O JPXNYGSRHUPYTF-CYBMUJFWSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 229940023019 aconite Drugs 0.000 description 1
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Chemical compound CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 229940107841 daunoxome Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- OESHPIGALOBJLM-REOHCLBHSA-N dehydroascorbate Chemical compound OC[C@H](O)[C-]1OC(=O)C(=O)C1=O OESHPIGALOBJLM-REOHCLBHSA-N 0.000 description 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 1
- 239000011615 dehydroascorbic acid Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ZSWDZQGVDJWLBK-UHFFFAOYSA-N dichloromethanediamine Chemical compound NC(N)(Cl)Cl ZSWDZQGVDJWLBK-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- CNHISCQPKKGDPO-UHFFFAOYSA-N ethyl 2-bromo-1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C1=CSC(Br)=N1 CNHISCQPKKGDPO-UHFFFAOYSA-N 0.000 description 1
- ARFLASKVLJTEJD-UHFFFAOYSA-N ethyl 2-bromopropanoate Chemical compound CCOC(=O)C(C)Br ARFLASKVLJTEJD-UHFFFAOYSA-N 0.000 description 1
- 229940098617 ethyol Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- FGIVSGPRGVABAB-UHFFFAOYSA-N fluoren-9-ylmethyl hydrogen carbonate Chemical compound C1=CC=C2C(COC(=O)O)C3=CC=CC=C3C2=C1 FGIVSGPRGVABAB-UHFFFAOYSA-N 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010057806 hemiasterlin Proteins 0.000 description 1
- 229930187626 hemiasterlin Natural products 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000002836 nanoconjugate Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- HUPQYPMULVBQDL-UHFFFAOYSA-N pentanoic acid Chemical compound CCCCC(O)=O.CCCCC(O)=O HUPQYPMULVBQDL-UHFFFAOYSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical class [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229930184737 tubulysin Natural products 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0212—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -N-C-N-C(=0)-, e.g. retro-inverso peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本發明提供新穎妥布賴森衍生物,其可單獨、作為藥物結合物或與其他化學療法組合適用作細胞毒性劑以在治療多個類型之癌症中提供治療益處。
Description
妥布賴森(tubulysin)為一類自黏液菌分離之細胞生長抑制四肽(Sasse F等人J.Antibiotics,2000,879)。妥布賴森之常見特徵為其四肽結構,其中僅Ile為天然存在之胺基酸且其他三者為複合非天然胺基酸:Mep(R-N-Me 2-哌啶甲酸)、Tuv(妥布纈胺酸)及Tut(妥布酪胺酸)或Tup(妥布苯丙胺酸)。隨後描述該家族之其他成員(Steinmettz等人,Angew.Chem.Int.2004版,4888)。大多數天然存在之妥布賴森展示與微管蛋白聚合抑制相關之對癌細胞株之pM細胞毒活性。妥布賴森之作用機制由Sasse描述(Khalil MW等人ChemBioChem,2006,678),其展示在抑制微管蛋白聚合方面妥布賴森A比β-微管蛋白黏合劑之其他長春花域(擬莖點黴屬毒素(phomopsin)、海兔毒素(dolastatin)及半星海膽素(hemiasterlin))更有效。妥布賴森展示毒性一貫高於海兔毒素。此外,報導妥布賴森A(Kaur G等人,Biochem.J,2006,235)會誘發癌細胞株中之細胞凋亡且在動物模型中除有效抗腫瘤活性外展示抗血管生成活性。在此等發現之後,投入相當大的努力以尋找與天然存在之妥布賴森具有類似效力之合成類似物。含N,O-縮醛之Tuv的存在向合成妥布賴森提出了難題且引起關於其穩定性之擔憂。若干群組鑑別用簡單甲基替換N,O-縮醛而不會顯著損失細胞毒活性之合成類似物(Patterson,A等人,Chem.Eur.J.2007,9534;Wipf P等人Org.Lett.2007,1605)。
若干報導揭露妥布賴森與葉酸之結合物(Leamon CP等人,Cancer Res.2008,9839)、環糊精奈米結合物(Schluep TS等人Clin.Cancer Res.2009,15:181)以及樹枝狀聚合物結合物(Floyd WC,ChemMedChem 2011,49)。一個報告揭露妥布賴森與單株抗體之結合(US2011/0027274)。
新穎妥布賴森衍生物可單獨、作為藥物結合物或與其他化學療法組合適用作細胞毒性劑以在治療多個類型之癌症中提供治療益處。
本發明提供具有式I結構之化合物:
其中:R1為CH3或CH2CH3;R2為H或CH3;R3為H或NH2;且n為1或2;或其醫藥學上可接受之鹽。
在一些態樣中,n為1且R1為甲基。
在一些態樣中,R2為甲基。
在一些態樣中,R3為NH2。
在一些態樣中,n為1,R1為甲基,R2為甲基且R3為NH2。
式I化合物具有細胞毒性且可適用於治療癌症。
本發明亦提供具有式II結構之化合物:
其中:R1為CH3或CH2CH3;R2為H或CH3;R4為CH3、(CH2)4NH2或(CH2)3NHC(=O)NH2;R5為H;C(CH3)(CH3);R6為NHC(=O)或CH2;n為1或2;且m為0、1、2或3。
在一些態樣中,n為1且R1為甲基。
在一些態樣中,R2為甲基。
在一些態樣中,R3為NH2。
在一些態樣中,n為1,R1為甲基,R2為甲基且R3為NH2。
在一些態樣中,R4為(CH2)4NH2。
在一些態樣中,R5為H。
在一些態樣中,R6為CH2。
在一些態樣中,m為1。
在一些態樣中,n為1,m為1,R1為甲基,R2為甲基且R3為NH2,R4為(CH2)4NH2,R5為H且R6為CH2。
式I化合物及式II化合物可經由習知方式與抗體結合以提供抗體藥物結合物(ADC)。在本發明之一些態樣中,式I及式II之化合物經由抗體離胺酸或半胱胺酸與抗體結合以提供抗體藥物結合物(ADC)。提供一些本發明之抗體藥物結合物,其中抗體為單株抗體。提供其他本發明之抗體藥物結合物,其中抗體對癌症抗原具有特異性。提供其他本發明之抗體藥物結合物,其中抗體為阿侖單抗(alemtuzumab)、貝伐單抗(bevacizumab)、貝倫妥單抗(brentuximab)、西妥昔單抗(cetuximab)、吉妥珠單抗(gemtuzumab)、伊派利單抗(ipilimumab)、奧伐木單抗(ofatumumab)、帕尼單抗(panitumumab)、利妥昔單抗(rituximab)、托西莫單抗(tositumomab)或曲妥珠單抗(trastuzumab)。
本發明亦提供一種醫藥組合物,其包含式I化合物或其醫藥學上可接受之鹽,以及醫藥學上可接受之載劑。提供醫藥組合物,其包含本發明之ADC及醫藥學上可接受之載劑。
本發明亦提供治療癌症之方法,其包含向患有癌症之個體投與有效量之式I化合物或式II化合物。本發明亦提供治療癌症之方法,其包含向患有癌症之個體投與有效量之結合抗體之式I化合物或式II化合物的抗體-藥物結合物。在本發明之一些態樣中,個體患有鱗狀細胞癌、小細胞肺癌、非小細胞肺癌、腸胃癌、霍奇金氏淋巴瘤(Hodgkin's lymphoma)、非霍奇金氏淋巴瘤、胰臟癌、神經膠母細胞瘤、神經膠質瘤、子宮頸癌、卵巢癌、肝癌、膀胱癌、乳癌、結腸癌、結腸直腸癌、子宮內膜癌、骨髓瘤、唾液腺癌、腎癌、基底細胞癌、黑色素瘤、前列腺癌、陰門癌、甲狀腺癌、睾丸癌、食道癌、頭頸癌、黏液性卵巢癌、膽管癌或乳頭狀腎癌。
亦提供治療癌症之方法,其包含向有需要個體投與包含式I化合物之醫藥組合物。本發明亦提供治療癌症之方法,其包含向有需要個體投與包含本發明之ADC的醫藥組合物。
在一些態樣中,該方法進一步包含投與至少一種其他治療劑。在一些態樣中,至少一種其他治療劑為放射性核種或化學治療劑。
本發明提供具有式I結構之化合物:
其中:R1為CH3或CH2CH3;R2為H或CH3;R3為H或NH2;且n為1或2;或其醫藥學上可接受之鹽。
在一些態樣中,n為1且R1為甲基。
在一些態樣中,R2為甲基。
在一些態樣中,R3為NH2。
在一些態樣中,n為1,R1為甲基,R2為甲基且R3為NH2。
本發明之式I化合物之特定實例包括化合物(Ii)至(Ivi)。
本發明提供具有式II結構之化合物:
(II)
其中:R1為CH3或CH2CH3;R2為H或CH3;R4為CH3、(CH2)4NH2或(CH2)3NHC(=O)NH2;R5為H;C(CH3)(CH3);R6為NHC(=O)或CH2;n為1或2;且m為0、1、2或3。
在一些態樣中,n為1且R1為甲基。
在一些態樣中,R2為甲基。
在一些態樣中,R3為NH2。
在一些態樣中,n為1,R1為甲基,R2為甲基且R3為NH2。
在一些態樣中,R4為(CH2)4NH2。
在一些態樣中,R5為H。
在一些態樣中,R6為CH2。
在一些態樣中,m為1。
本發明之式II化合物之特定實例包括化合物(IIi)至(IIiv)。
在本發明之一些態樣中,n為1。在本發明之其他態樣中,n為2。在n為2之情況下,哌啶環上之R1取代基可存在於環中之單一碳原子上,或可存在於環中之不同碳原子上。在本發明之一些態樣中,當n為1時,環之R1取代在氮對位。在本發明之其他態樣中,當n為1時,R1取代在哌啶環中氮的間位。
式I及式II之化合物可與抗體結合以形成抗體藥物結合物(ADC)。在ADC複合物中,式I化合物及式II化合物充當治療性部分,其藉由結合其之抗體遞送至所關注之治療性標靶。亦提供醫藥組合物,其包含由式I及式II化合物及抗體之結合形成之ADC。亦提供使用式I化合物及式II化合物製造ADC之方法。亦提供藉由投與本發明之ADC治療有
需要個體之癌症之方法。治療癌症之方法進一步提供投與本發明之ADC合併化學治療劑。
為了使本發明可更易於理解,首先對某些術語進行定義。在整個實施方式中,闡述其他定義。
前述書面說明書被認為足以使熟習此項技術者實踐實施例。前述描述及實例詳述某些實施例且描述發明人所涵蓋之最佳方式。然而,應瞭解,無論前文可在本文中如何詳細地呈現,實施例均可以多種方式實踐且申請專利範圍包括其任何等效物。
在詳細描述本發明之前,應瞭解本發明不限於特定組合物或方法步驟,因而可改變。除非上下文另外明確指示,否則如本說明書及隨附申請專利範圍中所使用,單數形式「一(a/an)」及「該(the)」包括複數個指示物。術語「一(a)」(或「一(an)」)以及術語「一或多個/種」及「至少一個/種」在本文中可互換使用。
此外,本文所用之「及/或」應視為兩種指定特徵或組分中之每一者具有或不具有另一者之特定揭示內容。因此,諸如本文「A及/或B」之短語中所用之術語「及/或」意欲包括「A及B」、「A或B」、「A」(單獨)及「B」(單獨)。同樣,諸如「A、B及/或C」之短語中所用之術語「及/或」意欲涵蓋以下態樣中之每一者:A、B及C;A、B或C;A或C;A或B;B或C;A及C;A及B;B及C;A(單獨);B(單獨);及C(單獨)。
除非另外規定,否則本文中所用之所有技術及科學術語均具有與本發明所屬領域之一般技術者通常所理解相同之含義。舉例而言,the Concise Dictionary of Biomedicine and Molecular Biology,Juo,Pei-Show,第2版,2002,CRC Press;The Dictionary of Cell and Molecular Biology,第3版,1999,Academic Press;及the Oxford Dictionary Of Biochemistry And Molecular Biology,Revised,2000,Oxford University
Press,向此項技術者提供本發明中所用之許多術語的通用辭典。
單位、字首及符號以其國際單位體系(Système International de Unites,SI)接受之形式表示。數值範圍包括界定該範圍之數字。除非另有指示,否則胺基酸序列以胺基至羧基方向從左向右書寫。本文所提供之標題不限制各種態樣,其可整體上參考本說明書。因此,下文緊接著定義之術語由整個說明書更充分定義。
應瞭解每當本文中用語言「包含」描述態樣時,則亦提供用術語「由……組成」及/或「基本上由……組成」所描述之類似態樣。
胺基酸在本文中可由其通常已知之三字母符號或由IUPAC-IUB生物化學命名法委員會(Biochemical Nomenclature Commission)所推薦之單字母符號來提及。
術語「抑制」、「阻斷」及「抑止」在本文中可互換使用且係指生物活性之任何統計學上顯著之減少,包括活性完全阻斷。舉例而言,「抑制」可指生物活性減少約10%、20%、30%、40%、50%、60%、70%、80%、90%或100%。
可使用此項技術所公認之技術分析細胞增殖,該等技術量測細胞分裂速率,及/或進行細胞分裂之細胞群體內之細胞分率,及/或細胞因終末分化或細胞死亡(例如併入胸苷)而自細胞群體損失之速率。
如在本文中可互換使用之術語「抗體」或「免疫球蛋白」包括全抗體及其任何抗原結合片段或單鏈以及其組合(例如雙特異性抗體)。
典型抗體包含藉由二硫鍵互連之至少兩個重(H)鏈和兩個輕(L)鏈。各重鏈包含重鏈可變區(本文中縮寫為VH)及重鏈恆定區(本文中縮寫為CH)。重鏈恆定區包含三個域CH1、CH2及CH3。各輕鏈包含輕鏈可變區(本文中簡化為VL)及輕鏈恆定區。輕鏈恆定區包含一個域CL。VH及VL區可進一步再分為穿插較為保守之區(稱為構架區(FW))
之高變區(稱為互補決定區(CDR))。各VH及VL由三個CDR及四個FW構成,胺基末端至羧基末端按以下次序排列:FW1、CDR1、FW2、CDR2、FW3、CDR3、FW4。重鏈及輕鏈之可變區含有與抗原相互作用之結合域。抗體之恆定區可介導免疫球蛋白與宿主組織或因子(包括免疫系統之各種細胞(例如效應細胞)及經典補體系統之第一組分(Clq))的結合。本發明之示例性抗體包括典型抗體scFv以及其組合,其中例如scFv共價連接(例如經由肽鍵或經由化學連接子)於典型抗體之重鏈及/或輕鏈之N端,或插入典型抗體之重鏈及/或輕鏈中。
術語「抗體」意謂經由免疫球蛋白分子之可變區內的至少一個抗原識別位點,識別且特異性結合於標靶,諸如蛋白質、多肽、肽、碳水化合物、聚核苷酸、脂質或上述各者之組合的免疫球蛋白分子。如本文所使用,術語「抗體」涵蓋完整多株抗體、完整單株抗體、抗體片段(諸如Fab、Fab'、F(ab')2及Fv片段)、單鏈可變片段(scFv)、經二硫化物穩定之scFv、多特異性抗體(諸如由至少兩個完整抗體及/或其抗原結合片段產生之雙特異性抗體)、嵌合抗體、人類化抗體、人類抗體、包含抗體之抗原決定部分之融合蛋白及包含抗原識別位點之任何其他經修飾之免疫球蛋白分子,只要該等抗體展現所需生物活性即可。
抗體可基於稱為α、δ、ε、γ及μ之免疫球蛋白之重鏈恆定域身分,而分別屬於免疫球蛋白之任何五個主要類別:IgA、IgD、IgE、IgG及IgM,或其子類(同型)(例如IgG1、IgG2、IgG3、IgG4、IgA1及IgA2)。免疫球蛋白之不同類別具有不同且熟知之次單元結構及三維組態。抗體可為裸的或與諸如毒素、放射性同位素等其他分子結合以形成ADC。
術語「抗原結合片段」係指完整抗體之一部分且係指完整抗體之抗原決定可變區。此項技術中已知抗體之抗原結合功能可藉由全長
抗體之片段進行。抗體片段之實例包括(但不限於)Fab、Fab'、F(ab')2及Fv片段、線性抗體、單鏈抗體及由抗體片段形成之多特異性抗體。
「單株抗體」係指參與單一抗原決定子或抗原決定基之高度特異性識別及結合的均質抗體。此與多株抗體形成對比,多株抗體通常包括針對不同抗原決定子之不同抗體。
術語「單株抗體」涵蓋完整與全長單株抗體以及抗體片段(諸如Fab、Fab'、F(ab')2、Fv)、單鏈可變片段(scFv)、包含抗體部分之融合蛋白及包含抗原識別位點之任何其他經修飾之免疫球蛋白分子。此外,「單株抗體」係指以多種方式,包括(但不限於)藉由融合瘤、噬菌體選擇、重組表現及轉殖基因動物(例如人類抗體在轉殖基因小鼠中之表現)製備之抗體。
術語「人類化抗體」係指衍生自非人類(例如鼠類)免疫球蛋白之抗體,其經工程改造最小非人類(例如鼠類)序列。通常,人類化抗體為其中來自CDR之殘基經來自非人類物種(例如小鼠、大鼠、兔或倉鼠)之CDR之殘基替換的人類免疫球蛋白,其具有所需特異性、親和力及能力(Jones等人,1986,Nature,321:522-525;Riechmann等人,1988,Nature,332:323-327;Verhoeyen等人,1988,Science,239:1534-1536)。在一些情況下,人類免疫球蛋白之FW殘基經來自非人類物種之抗體中之對應殘基置換,其具有所需特異性及/或親和力及/或能力。
術語「抗體-藥物結合物」(ADC)係指包含至少一種與至少一種式I化合物或式II化合物結合之結合至所關注之抗原決定基之抗體結合物。式I化合物及式II化合物可與抗體結合以形成抗體藥物結合物(ADC),由此式I化合物及式II化合物可充當治療性部分,其藉由結合其之抗體遞送至所關注之治療性標靶。
在一些態樣中,ADC包含兩個、三個、四個、五個、六個、七
個、八個、九個或十個治療部分。在一些特定態樣中,ADC包含兩個、三個或四個治療部分。在一些態樣中,所有治療部分均相同。在一些態樣中,至少一個治療部分不同於其他治療部分。
治療部分係指單一式I化合物分子或單一式II化合物分子。
術語「個體」係指任何動物(例如哺乳動物),包括(但不限於)人類、非人類靈長類動物、嚙齒動物及其類似動物,其為特定治療之接受者。通常,關於人類個體之術語「個體」及「患者」在本文中可互換使用。
術語「醫藥組合物」係指一種製劑,其呈允許活性成分具有生物活性之形式,且其不含對將投與組合物之個體具有不可接受之毒性的其他組分。此類組合物可無菌。
諸如「治療(treating)」或「治療(treatment)」或「治療(to treat)」或「緩解(alleviating)」或「緩解(to alleviate)」之術語係指以下兩者:(1)經診斷之病理性病狀或病症治癒、減緩、症狀減輕及/或進展停止的治療性手段;及(2)防止及/或減慢目標病理性病狀或病症發展的預防性或防治性手段。因此,需要治療者包括已患該病症者;傾向於患該病症者;以及有待預防該病症者。在某些態樣中,若患者展示某一類型癌症例如總體、部分或瞬時緩解,則根據本發明之方法,成功「治療」個體之癌症。
術語「癌症」、「腫瘤」、「癌性」及「惡性」係指或描述哺乳動物中通常以不受調控之細胞生長為特徵之生理病狀。癌症之實例包括(但不限於)癌瘤,包括腺癌、淋巴瘤、母細胞瘤、黑色素瘤、肉瘤及白血病。此類癌症之更特定實例包括鱗狀細胞癌、小細胞肺癌、非小細胞肺癌、腸胃癌、霍奇金氏淋巴瘤及非霍奇金氏淋巴瘤、胰腺癌、神經膠母細胞瘤、神經膠質瘤、子宮頸癌、卵巢癌、肝癌(諸如肝癌瘤及肝癌)、膀胱癌、乳癌(包括激素介導之乳癌,參見例如Innes等人
(2006)Br.J.Cancer 94:1057-1065)、結腸癌、結腸直腸癌、子宮內膜癌、骨髓瘤(諸如多發性骨髓瘤)、唾液腺癌、腎癌(諸如腎細胞癌及威耳姆士腫瘤(Wilms' tumor))、基底細胞癌、黑色素瘤、前列腺癌、陰門癌、甲狀腺癌、睾丸癌、食道癌、各種類型之頭頸癌及黏液來源癌(諸如黏液性卵巢癌)、膽管癌(肝)及腎乳頭狀癌。
如本文所用,術語「細胞毒性劑」廣泛定義且係指抑制或防止細胞功能及/或導致細胞破壞(細胞死亡),及/或發揮抗贅生性/抗增生作用之物質。舉例而言,細胞毒性劑直接或間接防止贅生性腫瘤細胞顯現、成熟或擴散。該術語亦包括僅產生細胞生長抑制作用而並非產生單純的細胞毒性作用的此類藥劑。該術語包括如下文所說明之化學治療劑以及其他HER2拮抗劑、抗血管生成劑、酪胺酸激酶抑制劑、蛋白質激酶、A抑制劑、細胞因子家族之成員、放射性同位素及毒素(諸如細菌、真菌、植物或動物來源之酶促活性毒素)。
術語「化學治療劑」為包含天然或合成化合物之術語「細胞毒性劑」之子組。化學治療劑之實例包括烷基化劑,例如氮芥、伸乙亞胺化合物、烷基磺酸酯及具有烷基化作用之其他化合物(諸如亞硝基脲、順鉑及達卡巴嗪(dacarbazine));抗代謝物,例如葉酸、嘌呤或嘧啶拮抗劑;有絲分裂抑制劑,例如長春花生物鹼(Vinca alkaloids)及鬼臼毒素之衍生物;細胞毒性抗生素及喜樹鹼衍生物。其他化學治療劑為阿米福汀(amifostine)(ETHYOL®)、順鉑、達卡巴嗪(DTIC)、放線菌素D(dactinomycin)、二氯甲二乙胺(氮芥)、鏈脲菌素(streptozocin)、環磷醯胺(cyclophosphamide)、卡莫司汀(carrnustine)(BCNU)、洛莫司汀(lomustine)(CCNU)、小紅莓(doxorubicin)(ADRIAMYCIN®)、小紅莓脂體(DOXIL®)、吉西他濱(gemcitabine)(GEMZAR®)、道諾黴素(daunorubicin)、道諾黴素脂體(DAUNOXOME®)、丙卡巴肼(procarbazine)、絲裂黴素(mitomycin)、
阿糖胞苷(cytarabine)、依託泊苷(etoposide)、甲胺喋呤(methotrexate)、5-氟尿嘧啶(5-FU)、長春鹼(vinblastine)、長春新鹼(vincristine)、博萊黴素(bleomycin)、太平洋紫杉醇(paclitaxel)(TAXOL®)、多烯紫杉醇(docetaxel)(TAXOTERE®)、阿地白介素(aldesleukin)、天冬醯胺酶(asparaginase)、白消安(busulfan)、卡鉑(carboplatin)、克拉屈濱(cladribine)、喜樹鹼(camptothecin)、CPT-11、10-羥基-7-乙基-喜樹鹼(SN38)、吉非替尼(gefitinib)(IRESSA®)、達卡巴嗪、氟尿苷(floxuridine)、氟達拉賓(fludarabine)、羥基脲(hydroxyurea)、異環磷醯胺(ifosfamide)、伊達比星(idarubicin)、美司鈉(mesna)、干擾素α、干擾素β、伊立替康(irinotecan)、米托蒽醌(mitoxantrone)、拓朴替康(topotecan)、亮丙立德(leuprolide)、甲地孕酮(megestrol)、美法侖(melphalan)、巰基嘌呤(mercaptopurine)、普卡黴素(plicamycin)、米托坦(mitotane)、培門冬酶(pegaspargase)、噴司他丁(pentostatin)、哌泊溴烷(pipobroman)、普卡黴素(plicamycin)、鏈脲菌素(streptozocin)、他莫昔芬(tamoxifen)、替尼泊試(teniposide)、睾內酯(testolactone)、硫鳥嘌呤(thioguanine)、噻替派(thiotepa)、尿嘧啶氮芥(uracil mustard)、長春瑞賓(vinorelbine)、苯丁酸氮芥芳香酶抑制劑及其組合。
根據本發明之方法,可向患者投與本發明之化合物及ADC以促使關於癌症之陽性治療反應。術語關於癌症治療之「陽性治療反應」係指與疾病相關之症狀改良。
舉例而言,疾病之改良之特徵可為完全反應。術語「完全反應」係指經正規化任何先前測試結果不存在臨床上可偵測之疾病。或者,疾病之改良可歸類為部分反應。「陽性治療反應」涵蓋由投與本發明化合物引起減小或抑制癌症之進展及/或持續時間、減小或改善癌症之嚴重性及/或改善其一或多種症狀。
在特定態樣中,此類術語係指一種、兩種或三種或三種以上投與本發明化合物後之結果:
(1)穩定、減小或消除癌細胞群體;
(2)穩定或減小癌生長;
(3)阻礙癌形成;
(4)根除、移除或控制原發性、區域性及/或轉移性癌症;
(5)減少死亡;
(6)增加無疾病、無復發、無進展及/或總存活期、持續時間或速率;
(7)增加反應速率、反應持久性或有反應或有緩解之患者的數量;
(8)降低住院率,
(9)降低住院時長,
(10)維持癌之大小且不增加或增加小於10%、較佳小於5%、較佳小於4%、較佳小於2%,及
(11)增加有緩解之患者之數量。
(12)降低治療癌症原本所需之輔助療法(例如化學療法或激素療法)之數量。
臨床反應可使用篩檢技術評估,該等篩檢技術為諸如PET、磁共振成像(MRI)掃描、x放射線成像、電腦斷層(CT)掃描、流動式細胞測量術或螢光活化細胞分類(FACS)分析、組織學、宏觀病理學及血液化學,包括(但不限於)可由ELISA、RIA、層析法及其類似方法偵測之變化。除此等陽性治療反應以外,進行治療之個體可在與疾病相關之症狀中經歷有益改良作用。
本發明化合物可與任何已知癌症療法組合使用,該等已知癌症療法包括已知有用、或已使用或目前正在使用以治療癌症(例如結腸
癌、肺癌、胃癌、頭頸鱗狀細胞癌及乳癌)之任何藥劑或藥劑之組合。抗癌劑包括用以治療惡性腫瘤(諸如癌生長)之藥物。藥物療法可單獨或與其他治療(諸如手術或放射療法)組合使用。視所涉及之器官之性質而定,可將若干類藥物用於癌症治療。舉例而言,乳癌通常藉由雌激素刺激,且可用使性激素不活化之藥物治療。類似地,前列腺癌可用使雄激素,即雄性性激素不活化之藥物治療。
用於本發明之某些方法之抗癌劑尤其包括抗體、抗代謝物、烷基化劑、拓撲異構酶抑制劑、微管靶向劑、激酶抑制劑、蛋白質合成抑制劑、免疫治療劑、激素療法、糖皮質激素、芳香酶抑制劑、mTOR抑制劑、化學治療劑、蛋白質激酶、B抑制劑、磷脂醯環己六醇3-激酶(PI3K)抑制劑、細胞週期素相關激酶(CDK)抑制劑、RLr9、CD289、酶抑制劑、抗TRAIL、MEK抑制劑及其類似物。
在組合療法包含投與本發明化合物合併投與另一治療劑之情況下,本發明方法涵蓋使用各別調配物或單一醫藥調配物共同投藥及以任一次序連續投藥。在一些態樣中,投與式I化合物、式II化合物及/或本文所述之ADC合併其他藥物,其中抗體或其抗原結合片段、變異體或衍生物及治療劑可以任一次序依序或同時(亦即並行地或在相同時間範圍內)投與。
組合療法可提供「協同作用」且證實「協同性」,亦即當活性成分一起使用時所達成之效應大於由分開使用化合物所產生之效應的總和。協同效應可在活性成分如下時獲得:(1)於經組合之單位劑量調配物中同時共調配及投與或遞送;(2)以各別調配物形式交替或並行遞送;或(3)藉由一些其他方案。當以交替療法遞送時,協同效應可在化合物例如藉由以各別注射器不同注射依序投與或遞送時獲得。一般而言,在交替療法期間,依序(亦即連續)投與有效劑量之各活性成分,然而在組合療法中,一起投與有效劑量之兩種或兩種以上活性成
分。
本發明之化合物及ADC(治療劑)可經口、非經腸、藉由吸入或表面途徑向患者投與。如本文所用之術語非經腸包括例如靜脈內、動脈內、腹膜內、肌肉內、皮下、經直腸或經陰道投藥。然而,在與本文中之教示相容之其他方法中,ADC可用以選擇性靶向本發明化合物以將治療劑直接遞送至有害細胞群體之部位,由此增加患病組織暴露於治療劑。
如本文中所論述,本發明之治療劑可以醫藥學上可接受之組合物投與以活體內治療癌症。通常,本發明化合物將調配成用於靜脈內投藥之溶液或調配成用於復水以製備靜脈內溶液(諸如用生理食鹽水、5%右旋糖或類似等張溶液)之凍乾濃縮物。醫藥組合物可包含醫藥學上可接受之載劑,包括例如水、離子交換劑、蛋白質、緩衝劑物質及鹽。亦可存在防腐劑及其他添加劑。載劑可為溶劑或分散介質。適用於本文所揭示之治療性方法之調配物描述於Remington's Pharmaceutical Sciences(Mack Publishing Co.)第16版(1980)中。
在任何情況下,無菌可注射溶液可藉由在適當溶劑中併入所需量之本發明之治療劑,隨後過濾滅菌來製備。此外,可將製劑封裝且以套組形式銷售。此類製品可具有標籤或包裝說明書,表明相關組合物適用於治療患有或易患疾病或病症之個體。
非經腸調配物可為單次劑量、輸注液或載入單次劑量,之後為維持劑量。此等組合物可以特定固定或可變之時間間隔,例如一天一次,或基於「按需要」來投與。
組合物可以單次劑量、多次劑量或以輸注方式經確定之時段投與。亦可調節劑量方案以提供最佳所需反應(例如治療性或預防性反應)。
用於治療癌症,包括例如結腸癌、肺癌、胃癌、頭頸鱗狀細胞
癌、黑色素瘤、胰臟癌、前列腺癌及乳癌之本發明組合物之治療有效劑量視許多不同因子而改變,該等因子包括投藥方式、標靶位點、患者(患者為人類或是動物)之生理狀態、所投與之其他藥劑及治療為預防性或是治療性的。通常,患者為人類,但亦可治療非人類哺乳動物,包括轉殖基因哺乳動物。治療劑量可使用熟習此項技術者已知之常規方法來滴定以使安全性及功效最佳。
待投與之本發明治療劑之量可容易由一般熟習此項技術者不經過度實驗來確定。影響投藥方式及各別藥劑量之因子包括(但不限於)疾病之嚴重性、疾病病史及進行治療之個體之年齡、身高、體重、健康狀況及身體狀況。類似地,待投與之抗-HER2結合分子(例如抗體或其片段、變異體或衍生物)之量將視投藥方式及個體經歷單次劑量或是多次劑量之此藥劑而定。
本發明亦提供本發明治療劑在製造用於治療一類癌症之藥物中之用途,該類癌症包括例如乳癌、結腸癌、肺癌、胃癌、頭頸鱗狀細胞癌、黑色素瘤、胰臟癌及前列腺癌。
本發明亦提供本發明治療劑在製造用於治療個體以治療一類癌症之藥物中之用途。在某些態樣中,該藥物用於已用至少一種其他療法預治療之個體中。
「預治療」或「前治療」為個體預期在接受包含本發明化合物之藥物之前接受一或多種其他療法(例如用至少一種其他抗癌療法治療)。個體不一定為用一或多種先前療法進行前治療之反應者。因此,接受藥物之個體可能已有反應,或可能尚未對用先前療法或先前療法中之一或多者進行前治療起反應,其中前治療包含多種療法。
本發明亦提供共同投與治療劑及至少一種其他療法,以單一組合物一起或以各別組合物同時或重疊之時間一起共同投與。
本發明亦提供治療劑在製造用於治療個體以治療癌症之藥物中
之用途,其中該藥劑在個體已用至少一種其他療法治療之前投與。
本發明之態樣可另外參考以下非限制性實例定義,該等非限制性實例詳細描述本發明之某些抗體的製備及使用本發明之抗體的方法。熟習此項技術者將顯而易知,在不悖離本發明之範疇的情況下,可對材料及方法作出許多修改。
除非另有說明,否則:
(i)除非另外說明,否則當在室溫或環境溫度,亦即在18-25℃之範圍內下進行操作時,溫度以攝氏度(℃)給出;
(ii)溶液經無水硫酸鈉或硫酸鎂乾燥;在高達30℃之浴溫下在減壓(4.5-30mmHg)下使用旋轉式蒸發器蒸發有機溶劑之有機物;
(iii)層析意謂矽膠急驟層析;薄層層析(TLC)在矽膠板上進行;
(iv)一般而言,繼該等反應過程之後為TLC或液相層析/質譜分析(LC/MS)且反應時間僅為說明之目的給出;
(v)最終產物具有令人滿意之質子核磁共振(NMR)光譜及/或質譜資料;
(vi)給出產量僅供說明之用且並不一定為可藉由努力方法開發所獲得之彼等產量;若需要更多物質則重複製備;
(vii)當給出時,除非另外說明,否則主要診斷質子之核磁共振(NMR)資料呈δ值形式,以相對於作為內標物之四甲基矽烷(TMS)之百萬分率(ppm)給出,在300或400MHz下於d6-DMSO中得以測定;
(viii)化學符號具有其常見含義;
(ix)溶劑比率以體積:體積(v/v)術語給出;
(x)化合物之純化使用以下方法中之一或多者進行:
a)常規矽膠急驟層析;
b)Isco IscoCombiflash®分離系統之矽膠急驟層析:
RediSep正相急驟管柱,流動速率30-40ml/min(ISCO MPLC)。
c)Gilson半製備型HPLC分離系統:YMC pack ODS-AQ管柱,100×20mm,S 5μm 12nm,水(0.1%三氟乙酸)及乙腈(0.1%三氟乙酸)作為溶劑,20min;及
(xi)使用下列縮寫:
向於(2R,4R)-4-甲基哌啶-2-甲酸(2g,13.97mmol)於MeOH(40mL)及水(40.0mL)中之溶液中添加多聚甲醛(2.52g,27.94mmol)及Pd/C(10%)(0.8g,7.52mmol)。在氫氣氛圍下,在室溫下攪拌反應混合物隔夜。由TLC,反應完成。再添加1當量多聚甲醛(2.52g,27.94mmol)且再攪拌反應混合物24小時。TLC指示反應完成且過濾反應混合物,用MeOH(2×30mL)洗滌催化劑。真空濃縮濾液得到呈白色固體狀之粗產物,用乙醚(3×30mL)洗滌,高真空乾燥隔夜,產生
呈白色固體狀之(2R,4R)-1,4-二甲基哌啶-2-甲酸(1)(1.870g,85%)。LC-MS:158(M+1);1H NMR(400MHz,D2O)δ ppm 0.97(d,J=5.52Hz,3 H),1.54(br.s,1 H),1.71-1.87(m,3 H),1.91-2.07(m,1 H),2.84(s,3 H),3.13(td,J=8.41,3.76Hz,1 H),3.35(m,1 H),3.65(m,1 H)。
在室溫下在攪拌下將Boc2O(243.0g,1.1mol)逐滴添加至(R)-3-胺基-4-甲基戊酸(可購得)(133.0g,1.0mol)及Na2CO3(212g,2.0mol)於丙酮(1L)及水(1L)中之懸浮液中。攪拌反應混合物隔夜且減壓移除有機溶劑。用水(1L)稀釋殘餘物且用EtOAc(500ml×3)洗滌。用2N HCl溶液酸化水相至pH=3且用EtOAc(800mL×3)萃取所得混合物。用鹽水洗滌(800mL×1)合併之萃取物,乾燥(Na2SO4)且濃縮,得到呈油狀之化合物(2)(224.0g,產率97%),其未經進一步純化即用於下一步驟。
在0℃下在攪拌下將三乙胺(67g,0.61mol)添加至中間物2(140.0g,0.61mol)及N,O-二甲基羥胺鹽酸鹽(74.1g,0.76mol)於CH2Cl2(1.4L)中之懸浮液中。攪拌懸浮液0.5小時且在0℃下數份添加EDCI(74g,0.61mol)。在0℃下攪拌反應混合物2小時且添加水(800mL)。分離有機相,用5% KHSO4溶液(800mL×3)、飽和NaHCO3溶液(800mL×3)及鹽水(800mL×1)洗滌,乾燥(Na2SO4)且濃縮至乾燥。矽膠急驟管柱層析(EtOAc/己烷=1:5)純化殘餘物,得到呈油狀之化合物
(3)(141.0g,產率84%)。1H NMR(300MHz,CDCl3):δ 5.26(m,1H),3.75(m,1H),3.70(s,3H),3.15(s,3H),2.60~2.80(m,2H),1.85(m,1H),1.41(s,9H),0.90(d,J=6.6Hz,3H),0.88(d,J=6.6Hz,3H)。
在0℃下在攪拌下將碘乙烷(250.0g,1.6mol)添加至中間物3(55.0g,0.2mol)於DMF(1.1L)中之溶液中。接著在0℃下數份添加NaH(60%懸浮液,24.0g,0.60mol)且使反應混合物升溫至室溫且攪拌12小時。用(2L)小心地淬滅反應物且添加EtOAc(2L)。分離有機相,用5% KHSO4溶液(800mL×3)、飽和NaHCO3溶液(800mL×3)及鹽水(800mL×1)洗滌,乾燥(Na2SO4)且濃縮至乾燥。藉由矽膠急驟管柱層析(EtOAc/己烷=1:10)純化殘餘物得到呈油狀之(R)-乙基(1-(甲氧基(甲基)胺基)-4-甲基-1-側氧基戊-3-基)胺基甲酸第三丁酯(35.1g,產率58%)。1H NMR(300MHz,CDCl3):δ 3.70(s,3H),3.65(m,1H),3.10~3.30(m,5H),2.50~2.95(m,2H),1.90~2.20(m,1H),1.40~1.55(m,9H),1.10(t,J=7.2Hz,3H),0.90(d,J=6.6Hz,3H),0.88(d,J=6.6Hz,3H)。
在-78℃下,在N2下,在攪拌下,經1小時將n-BuLi之溶液(106mL,2.5N己烷溶液,0.17mol)逐滴添加至中間物50(74g,0.24mol)於無水THF(500mL)中之溶液中。再攪拌懸浮液30min,接著在-78℃下經30min逐滴添加中間物4(51.0g,0.17mol)於無水THF(300mL)中之溶液。在-78℃下攪拌反應混合物1小時,接著升溫至室溫且攪拌
12小時。用20%氯化銨水溶液(1L)淬滅反應物且減壓移除有機溶劑。用EtOAc(800mL×3)萃取所得混合物。用5%KHSO4溶液(800mL×3)、飽和NaHCO3溶液(800mL×3)及鹽水(800mL×1)洗滌合併之有機相,乾燥(Na2SO4)且濃縮至乾燥。藉由矽膠急驟管柱層析純化粗物質(EtOAc/己烷=1:10),得到呈油狀之(R)-(1-(4-(((第三丁基二甲基矽烷基)氧基)甲基)噻唑-2-基)-4-甲基-1-側氧基戊-3-基)(乙基)胺基甲酸第三丁酯(58.1g,產率73%)。1H NMR(300MHz,CDCl3):δ 7.53(m,1H),4.90(s,2H),4.04(m,1H),3.35(m,2H),3.15(m,2H),2.00(m,1H),1.40(s,9H),0.80~1.20(m,18H),0.14(s,6H)。
在室溫下,在攪拌下,經0.5小時之時段將LiBH4(4.8g,0.22mol)數份添加至中間物5(47.1g,0.1mol)於甲醇(500ml)中之溶液中。攪拌懸浮液2小時且減壓移除溶劑。將殘餘物溶解於EtOAc(800mL)中且用飽和NaHCO3溶液(500mL×3)及鹽水(500mL×1)洗滌所得溶液,乾燥(Na2SO4)且濃縮至乾燥。藉由急驟管柱層析(EtOAc/己烷=1:6)純化粗物質得到tert-butyl((1R,3R)-1-(4-(((第三丁基二甲基矽烷基)氧基)甲基)噻唑-2-基)-1-羥基-4-甲基戊-3-基)(乙基)胺基甲酸第三丁酯(13.5g,產率28%)及其異構體(6')(21.0g,產率45%)。1H NMR(300MHz,CDCl3)δ ppm -0.06-0.05(m,6 H)0.76-0.89(m,15 H)1.12(t,J=6.97Hz,3 H)1.39(s,9 H)1.55-2.05(m,3 H)2.86-3.21(m,2 H)3.76-3.96(m,1 H)4.73(d,J=1.13Hz,4 H)7.01(s,1 H)。
在0℃下,在攪拌下,經10min將乙醯氯(45.2g,0.58mol)逐滴添加至中間物6(34.0g,72mmol)於吡啶(500mL)中之溶液中。使反應混合物升溫至室溫且攪拌12小時。用水(200mL)淬滅反應物且減壓移除溶劑。用CH2Cl2(800mL)處理殘餘物且用5%KHSO4溶液(800mL×3)、飽和NaHCO3溶液(800mL×3)及鹽水(800mL×1)洗滌所得混合物,乾燥(Na2SO4)且濃縮至乾燥。藉由矽膠急驟管柱層析(EtOAc/己烷=1:10)純化粗物質得到呈油狀之乙酸(1R,3R)-3-((第三丁氧羰基)(乙基)胺基)-1-(4-(((第三丁基二甲基矽烷基)氧基)甲基)噻唑-2-基)-4-甲基戊酯(25.7g,產率69%)。1H NMR(300MHz,CDCl3):δ 7.15(m,1H),5.95(m,1H),4.84(s,2H),4.04(m,1H),3.10(m,2H),2.35(m,1H),2.15(s,3H),2.00(m,1H),1.70(m,1H),1.45(s,9H),1.25(t,J=7.2Hz,3H),0.80~1.10(m,15H),0.08(s,6H)。
在0℃下在攪拌下將氟化四丁基銨(65.3g,0.25mol)於THF(200mL)中之溶液逐滴添加至中間物7(25.7g,50mmol)於THF(300mL)中之溶液中。使反應混合物升溫至室溫且攪拌4小時。添加水(800mL)且減壓移除有機溶劑。用CH2Cl2(800mL)處理殘餘物且用5%KHSO4溶液(800mL×3)、飽和NaHCO3溶液(800mL×3)及鹽水(800mL×1)洗滌所得混合物,乾燥(Na2SO4)且濃縮至乾燥。藉由矽膠急驟管柱層析(EtOAc/己烷=1:4)純化粗物質得到呈油狀之乙酸(1R,3R)-3-((第三丁氧羰基)(乙基)胺基)-1-(4-(羥基甲基)噻唑-2-基)-4-甲基戊酯(19.5g,產率98%)。1H NMR(300MHz,CDCl3):δ 8.26(m,1H),5.95(m,1H),4.83(m,2H),4.10(m,1H),3.17(m,2H),2.40(m,1H),2.20(s,3H),2.18(m,1H),1.75(m,1H),1.56(s,9H),1.10~1.30(m,3H),0.80~1.05
(m,6H)。
將戴斯-馬丁試劑(Dess-Martin reagent)(32.7g,75mmol)添加至中間物8(20.0g,50mmol)於二氯甲烷(300mL)中之溶液中且在室溫下攪拌反應混合物12小時。分別用氫氧化鈉溶液(1N,300mL×3)、硫代硫酸鈉溶液(1N,300mL×3)、飽和NaHCO3(300mL×3)溶液及鹽水(300mL×1)洗滌混合物。乾燥(Na2SO4)有機層且濃縮至乾燥,得到對應醛。將此粗醛溶解於第三丁醇(500mL)中且在室溫下經1小時逐滴添加亞氯酸鈉(80%,36.4g,320mmol)及磷酸二氫鈉單水合物(105g,0.77mol)於水(300mL)中之溶液。攪拌反應混合物3小時且用鹽酸溶液(0.1N,500mL)稀釋。用EtOAc(500mL×1)萃取所得混合物且用5%KHSO4溶液(500mL×3)及鹽水(500mL×1)洗滌合併之有機層,經Na2SO4乾燥且濃縮至乾燥。藉由矽膠急驟管柱層析(CH2Cl2/MeOH=100:5)純化殘餘物,得到2-((1R,3R)-1-乙醯氧基-3-((第三丁氧羰基)(乙基)胺基)-4-甲基戊基)噻唑-4-甲酸(15.4g,產率58%)。1H NMR(300MHz,CDCl3):δ 9.90(br s,1H),8.27(s,1H),5.96(m,1H),4.07(m,1H),3.15(m,1H),2.35(m,1H),2.20(s,3H),2.18(m,1H),1.75(m,1H),1.45(s,9H),1.20(t,J=7.2Hz,3H),0.98(d,J=6.6Hz,3H),0.88(d,J=6.6Hz,3H)。
在0℃下向中間物9(6.5g,15.68mmol)於DCM(60mL)中之溶液
中逐滴添加TFA(30mL)。在0℃下攪拌混合物1小時。真空蒸發溶劑得到粗2-((1R,3R)-1-乙醯氧基-3-(乙胺基)-4-甲基戊基)噻唑-4-甲酸。此粗產物未經進一步純化即用於下一步反應中(7.2公克)。LC-MS:315(M+1)。
向中間物10(5g,11.67mmol)及碳酸氫鈉(9.80g,116.71mmol)於丙酮(300mL)及水(150mL)之混合物中之溶液中添加碳酸(9H-茀-9-基)甲酯(2,5-二側氧基吡咯啶-1-基)酯(3.94g,11.67mmol)。在室溫下攪拌混合物隔夜。LCMS指示反應完成。用鹽酸將混合物酸化至(pH 2)且真空蒸發丙酮。用DCM(3×300mL)萃取產物。用0.1% HCl溶液(200mL)、鹽水(200mL)洗滌合併之有機物,經Na2SO4乾燥且真空蒸發。藉由急驟層析(矽膠,MeOH/DCM,0%至5%之MeOH)純化殘餘物得到呈白色固體狀之2-((1R,3R)-3-((((9H-茀-9-基)甲氧基)羰基)(乙基)胺基)-1-乙醯氧基-4-甲基戊基)噻唑-4-甲酸(3.53g,54.6%)。LC-MS:537.2(M+1);1H NMR(400MHz,氯仿-d)δ ppm 0.84(d,J=6.78Hz,3 H),0.92-1.05(m,5 H),1.14(d,J=3.01Hz,1 H),1.73(dt,J=10.23,6.43Hz,1 H),1.92-2.05(m,1 H),2.12-2.27(m,4 H),2.28-2.44(m,1 H),2.90-3.33(m,2 H),3.98(t,J=9.29Hz,1 H),4.12-4.32(m,1 H),4.47-4.82(m,2 H),5.95(dd,J=10.92,2.89Hz,1 H),7.29-7.45(m,4 H),7.55-7.69(m,2 H),7.72-7.81(m,2 H),8.22-8.29(m,1 H)。
將DMAP(106g,0.86mol)添加至第三丁氧羰基-L-4-硝基-苯丙胺酸(1800g,0.58mol)及梅爾德倫氏酸(92g,0.64mol)於二氯甲烷(1.5L)中之溶液中。在-5℃下在N2氛圍下冷卻所得溶液,隨後經1h添加含DCC(240g,1.16mol)之二氯甲烷(1L)。在0至5℃下攪拌混合物隔夜。接著藉由過濾移除沈澱之N,N'-二環已基脲且用5%水溶液HCl(1L×3)及鹽水(1L×1)洗滌濾液且經MgSO4乾燥。在藉由過濾移除MgSO4之後,使有機相濃縮至乾燥。用EtOAc/己烷(1:1,500mL)濕磨殘餘物且乾燥,得到呈黃色固體狀之(S)-(1-(2,2-二甲基-4,6-二側氧基-1,3-二氧雜環己烷-5-基)-3-(4-硝基苯基)-1-側氧基丙-2-基)胺基甲酸第三丁酯(130.0g,產率51%)。
在-5℃下在N2下將AcOH(400mL)添加至中間物12(130.0g,0.298mol)於二氯甲烷(1.5L)中之溶液中。經2小時以小份添加固體NaBH4(22.7g,0.597mol)(釋放氣體且放熱)。在-5℃下再攪拌3h之後,TLC指示反應完成。用鹽水(1L)淬滅混合物。分離有機層,且依序用水(1L×2)、飽和NaHCO3水溶液(1L×3)及鹽水(1L×3)洗滌,且經MgSO4乾燥。濾液濃縮至乾燥且得到呈黃色固體狀之(R)-(1-(2,2-二甲基-4,6-二側氧基-1,3-二氧雜環己烷-5-基)-3-(4-硝基苯基)丙-2-基)胺基甲酸第三丁酯(70.3g,產率55%)。1H NMR(300MHz,CDCl3):δ 8.18(d,J=8.7Hz,2H),7.41(d,J=8.7Hz,2H),4.58(m,1H),4.29(m,1H),
3.85(m,1H),2.97(d,J=6.6Hz,2H),2.27(m,2H),1.80(s,3H),1.76(s,3H),1.35(s,9H)。
將K2CO3(35g,0.25mol)及MeI(36g,0.25mol)添加至中間物13(70.3g,0.167mol)於丙酮(400mL)及DMF(400mL)中之溶液中。在室溫下攪拌混合物隔夜。TLC顯示起始物質耗盡。添加水(2L)且再攪拌混合物1小時。藉由過濾收集沈澱之固體,用水洗滌,乾燥得到呈淺黃色固體狀之(S)-(1-(4-硝基苯基)-3-(2,2,5-三甲基-4,6-二側氧基-1,3-二氧雜環己烷-5-基)丙-2-基)胺基甲酸第三丁酯(34.5g,產率47%)。1H NMR(300MHz,CDCl3):δ 8.17(d,J=8.7Hz,2H),7.34(d,J=8.7Hz,2H),4.22(m,1H),3.85(m,1H),2.85(m,2H),2.22(m,2H),1.73(s,3H),1.73(s,3H),1.52(s,3H),1.31(s,9H)。
將中間物14(34.5g,79.1mmol)溶解於甲苯(500ml)中。在回流下加熱溶液40小時。TLC指示反應完全。移除溶劑得到(5R)-3-甲基-5-(4-硝基苯甲基)-2-側氧基吡咯啶-1-甲酸第三丁酯(30g),其未經進一步純化即用於下一步驟。
將K2CO3(22g,0.16mol)添加至中間物15(30g,79mmol)於
MeOH(300mL)中之溶液中。將在室溫下攪拌混合物3小時。TLC展示完全轉化。移除溶劑,將殘餘物溶解於二氯甲烷(500ml)中,用鹽水(500mL×3)洗滌且經MgSO4乾燥。在藉由過濾移除MgSO4之後,使有機相濃縮至乾燥。藉由矽膠層析(EtOAc/己烷=1:10)進一步純化殘餘物且得到呈1:1非對映異構混合物之(4R)-4-((第三丁氧羰基)胺基)-2-甲基-5-(4-硝基苯基)戊酸甲酯(23.5g,產率81%,兩個步驟)。1H NMR(300MHz,CDCl3):δ 8.13(d,J=8.7Hz,2H),7.34(d,J=8.7Hz,2H),4.43(m,1H),3.85(m,1H),3.65(s,3H),2.85(m,2H),2.65(m,1H),1.85(m,1H),1.50(m,1H),1.30(s,9H),1.15(t,J=6.6Hz,3H)。
使50g化合物(16)經歷對掌性層析,其中使用SFC(超臨界流體層析),經Chiralpak ID 21×250mm,5μ管柱,使用移動相A 90%二氧化碳及移動相B異丙醇10%,流動速率為60ml/min。在40℃下進行分離且在270nM下偵測。實現基線分離且分離兩個溶離份。峰值B為所需(2S,4R)-4-((第三丁氧羰基)胺基)-2-甲基-5-(4-硝基苯基)戊酸甲酯且以固體狀獲得,27.4g(55%)。經Chiralpak IA管柱4.6×250mm,5μ,使用含10% 1:1甲醇:異丙醇之具有0.1%二乙胺改質劑之己烷,>99:1非對映異構過量。LC/MS(2分鐘,Acid_CV10.olp方法367(M+1),1.16分鐘。
1H NMR(400MHz,甲醇-d4)δ ppm 8.16(d,J=8.53Hz,2 H)7.46(d,J=8.53Hz,2 H)3.79-3.93(m,1 H)3.68(s,3 H)2.90-2.99(m,1H)2.71-2.81(m,1 H)2.47-2.59(m,1 H)1.81-1.95(m,1 H)1.55-1.66(m,1 H)1.32(s,9 H)1.21-1.25(m,2 H)1.16(d,J=7.03Hz,3
H)。
在微波中在130℃下加熱中間物17於6N HCl水溶液(8.0mL,263.30mmol)中之溶液30min。使反應混合物凍乾,得到呈固體狀之(2S,4R)-4-胺基-2-甲基-5-(4-硝基苯基)戊酸。產物未經進一步純化即用於下一步反應中(3.2g)。LC-MS:253(M+1);1H NMR(400MHz,D2O)δ ppm 1.12(d,J=7.28Hz,3 H),1.62-1.76(m,1 H),1.90-2.02(m,1 H),2.56-2.68(m,1 H),3.02-3.11(m,2 H),3.58-3.69(m,1 H),7.47(d,J=8.53Hz,2 H),8.18(d,J=8.78Hz,2 H)。
向中間物18(0.43g,1.49mmol)及NaHCO3(1.251g,14.89mmol)於丙酮(30mL)及水(15mL)之混合物中之溶液中添加碳酸(9H-茀-9-基)甲酯2,5-二側氧基吡咯啶-1-基酯(0.502g,1.49mmol)。在室溫下攪拌混合物隔夜。LC/MS指示反應完成。用鹽酸將混合物酸化至pH 2且真空蒸發丙酮。用DCM(3×60mL)萃取產物。用1N HCl溶液(40mL)、鹽水(40mL)洗滌合併之有機物,經Na2SO4乾燥且真空蒸發。藉由矽膠層析(0%至100% EtOAc/DCM)純化殘餘物,得到呈白色固體狀之(2S,4R)-4-氟基(((9H-茀-9-基)甲氧基)羰胺基)-2-甲基-5-(4-硝基苯基)戊酸(0.630g,89%)。LC-MS:475.5(M+H);1H NMR(400MHz,氯仿-d)δ ppm 0.81-1.06(m,1 H),1.08-1.28(m,2 H),1.33-1.75(m,
1 H),1.77-2.11(m,1 H),2.36-2.69(m,2 H),2.76-3.18(m,1 H),3.43-4.08(m,1 H),4.09-4.19(m,1 H),4.21-4.53(m,2 H),4.54-4.80(m,1 H),7.18-7.58(m,8 H),7.66-7.82(m,2 H),7.95-8.17(m,2 H),8.67(br.s.,1 H)。
將DIEA(0.419mL,2.40mmol)添加至中間物19(0.380g,0.80mmol)於DCM(4.5mL)中之溶液中,且在室溫下攪拌混合物5min,接著將2-氯三苯甲基氯樹脂(0.4mmol/g(裝載量),0.5g,0.80mmol)添加至混合物中。在室溫下振盪混合物隔夜,用DMF(3×6mL)、MeOH(3×6mL)及DCM(3×6mL)洗滌所得樹脂,接著在室溫下用DIEA(0.419mL,2.40mmol)及MeOH/DCM(1:1,5mL)處理30min。過濾所得樹脂,用DMF(3×6mL)、MeOH(3×6mL)及DCM(3×6mL)洗滌,高真空乾燥隔夜。自樹脂裂解少量化合物且藉由LC/MS分析。所得樹脂用於下一步反應中。LC/MS:475(M+1)。
向樹脂中間物20(0.5g,0.80mmol)中添加含20%哌啶之DMF(5mL)。在室溫下振盪混合物6min,過濾所得樹脂,用DMF(3×6mL)、MeOH(3×6mL)、DCM(3×6mL)洗滌,且真空乾燥。自樹脂裂解少量化合物,藉由LC/MS分析,其指示反應完成。所得樹脂用於下一步反應中。LC/MS:253(M+H)。
在室溫下向中間物21樹脂(0.5g,1.88mmol)中添加中間物11(1.108g,2.07mmol)、HATU(1.428g,3.76mmol)、2,4,6-三甲基吡啶(0.500mL,3.76mmol)及DIEA(0.656mL,3.76mmol)於DMF(5mL)中之溶液。在室溫下振盪混合物兩小時,且過濾所得樹脂,用DMF(3×6mL)、MeOH(3×6mL)及DCM(3×6mL)洗滌,且真空乾燥。自樹脂裂解少量化合物,藉由LC/MS分析,其指示反應完成。所得樹脂用於下一步驟中。LC/MS:771(M+H)所得樹脂用於下一步驟中。
向樹脂中間物22(0.5g,0.80mmol)中添加含20%哌啶之DMF(5mL)。在室溫下振盪混合物6min,過濾所得樹脂,用DMF(3×6mL)、MeOH(3×6mL)、DCM(3×6mL)洗滌,且真空乾燥。自樹脂裂解少量化合物,藉由LC/MS分析,指示反應完成。所得樹脂用於下一步反應中。LC-MS:549(M+1)。
經10min經由插管向(2S,3S)-2-(((9H-茀-9-基)甲氧基)羰胺基)-3-
甲基戊酸(Fmoc-異白胺酸)(7g,19.81mmol)及吡啶(1.602mL,19.81mmol)於DCM(120mL)中之溶液中添加DAST(3.11mL,23.77mmol)於DCM(20mL)中之溶液。在室溫下攪拌反應混合物1小時,用DCM(80mL)稀釋,用冰冷水(2×200mL)洗滌,有機層經MgSO4乾燥,過濾且真空蒸發,得到呈白色固體狀之(2S,3S)-1-氟-3-甲基-1-側氧基戊-2-基胺基甲酸(9H-茀-9-基)甲酯(6.65g,94%)。藉由將Fmoc-Ile-F(5mg)溶解於無水MeOH(0.3mL)及DIEA(0.030mL)中進行酯化測試以確保定量醯基氟形成,且在室溫下反應15min。接著真空蒸發混合物且藉由LCMS分析,展示存在小於1%之Fmoc-Ile-OH。
1H NMR(400MHz,CDCl3)δ ppm 0.83-1.12(m,6 H)1.18-1.37(m,1 H)1.42-1.59(m,1 H)2.01(br.s.,1 H)4.26(t,J=6.78Hz,1 H)4.44-4.63(m,3 H)5.20(d,J=8.53Hz,1 H)7.31-7.39(m,2 H)7.40-7.47(m,2 H)7.61(d,J=7.28Hz,2 H)7.80(d,J=7.53Hz,2 H)。
在室溫下向樹脂中間物23(0.5g,0.80mmol)中添加中間物24(0.569g,1.60mmol)、DMAP(4.89mg,0.04mmol)及DIEA(0.419mL,2.40mmol)於DCM(5mL)中之溶液。在室溫下振盪混合物隔夜,過濾所得樹脂,用DMF(3×6mL)、MeOH(3×6mL)、DCM(3×6mL)洗滌,高真空乾燥。自樹脂裂解少量化合物,且藉由LC/MS分析。LC/MS指示反應完成。所得樹脂用於下一步反應中。LC-MS:884(M+H)。
向樹脂中間物25(0.5g,0.80mmol)中添加含20%哌啶之DMF(5mL)。在室溫下振盪混合物6min,過濾所得樹脂,用DMF(3×6mL)、MeOH(3×6mL)、DCM(3×6mL)洗滌,且真空乾燥。自樹脂裂解少量化合物,藉由LC/MS分析,其指示反應完成。所得樹脂用於下一步反應中。LC/MS:662(M+1)。
向樹脂中間物26(0.5g,0.80mmol)中添加中間物1(0.252g,1.60mmol)、HATU(0.608g,1.60mmol)、2,4,6-三甲基吡啶(0.320mL,2.40mmol)及DIEA(0.419mL,2.40mmol)於DMF(5mL)中之溶液。在室溫下振盪混合物2小時,過濾所得樹脂,用DMF(3×6mL)、MeOH(3×6mL)及DCM(3×6mL)洗滌,且真空乾燥。自樹脂裂解少量化合物,藉由LC/MS分析,其指示反應完成。所得樹脂用於下一步反應中。LC-MS:801(M+1)。
向樹脂中間物27中添加脫水氯化錫(II)(1.805g,8.00mmol)及乙
酸鈉(0.197g,2.40mmol)於DMF(5mL)中之溶液。在室溫下振盪混合物4小時。過濾所得樹脂,用DMF(3×6mL)、MeOH(3×6mL)及DCM(3×6mL)洗滌,且真空乾燥。自樹脂裂解少量化合物,且藉由LC/MS分析,其指示反應完成。所得樹脂用於下一步驟中。LC-MS:771(M+H)。
在室溫下向樹脂中間物28(0.1g,0.16mmol)中添加DCM(1mL)、水(0.200mL)及TFA(1mL)。在室溫下振盪混合物20min,接著過濾,且用水/TFA(1:1,3×2mL)洗滌,且真空蒸發濾液。藉由逆相HPLC(ACN/H2O 0.1% TFA,ACN為5%至50%,14min內)純化殘餘物。將純溶離份凍乾,得到呈固體狀之(2S,4R)-4-(2-((1R,3R)-1-乙醯氧基-3-((2S,3S)-2-((2R,4R)-1,4-二甲基哌啶-2-甲醯胺基)-N-乙基-3-甲基戊醯胺基)-4-甲基戊基)噻唑-4-甲醯胺基)-5-(4-胺基苯基)-2-甲基戊酸(0.050g,35.3%)。LC/MS:771.8[M+1];1H NMR(400MHz,甲醇-d 4)d ppm 7.8(s,1 H),7.30(d,J=8.53Hz,2 H),7.08-7.18(m,2 H),5.66(d,J=13.05Hz,1 H),4.57(d,J=8.53Hz,1 H),4.29(ddd,J=9.98,6.71,2.89Hz,1 H),3.90(br.s.,1 H),3.73(d,J=6.27Hz,1 H),3.24-3.33(m,1 H),2.84(d,J=7.28Hz,2 H),2.68(br.s.,3 H),2.40-2.53(m,2 H),2.20-2.36(m,1 H),2.03-2.12(m,4 H),1.75-2.00(m,7 H),1.64(ddd,J=14.12,10.23,4.02Hz,2 H),1.42-1.57(m,2 H),1.30(t,J=7.15Hz,3 H),1.01-1.17(m,7 H),0.88-0.98(m,7 H),0.84(t,J=7.40Hz,3 H),0.77d,J=6.53Hz,3 H)。
向2-乙基哌啶-2-甲酸(320mg,1.65mmol)於MeOH(4.0mL)及水(4.0mL)中之溶液中添加多聚甲醛(372mg,4.13mmol)及Pd/C(10%)(88mg,0.83mmol)。添加1當量碳酸鈉(175mg,1.65mmol)且在室溫下在氫氣氛圍下攪拌反應混合物隔夜。LC/MS指示起始物質完全轉化。經由矽藻土過濾反應混合物。用MeOH(2×30mL)洗滌濾餅。真空濃縮濾液得到粗產物。使粗固體懸浮於甲醇(50mL)中且過濾所得懸浮液且濃縮濾液,得到呈固體狀之2-乙基-1-甲基哌啶-2-甲酸(202mg,71.4%)。LC/MS:172(M+1);1H NMR(400MHz,CD3OD)δ ppm 3.58(td,J=12.80,3.51Hz,1 H),3.09-3.20(m,1 H),2.81(s,3 H),2.17-2.29(m,1 H),1.54-1.84(m,7 H),0.98(t,J=7.40Hz,3 H)。
向樹脂中間物26(0.2g,0.32mmol)中添加中間物29(0.082g,0.48mmol)、HATU(0.243g,0.64mmol)、2,4,6-三甲基吡啶(0.127mL,0.96mmol)及DIEA(0.168mL,0.96mmol)於DMF(5mL)中之溶液。在室溫下振盪混合物2小時,過濾所得樹脂,用DMF(3×4mL)、MeOH(3×4mL)及DCM(3×4mL)洗滌,且真空乾燥。自樹脂裂解少量化合物,且藉由LCMS分析,其指示反應完成。所得樹脂用於下一步反應中。LC/MS:815(M+H)。
向樹脂中間物30中添加氯化錫(II)二水合物(0.544g,2.41mmol)及乙酸鈉(0.059g,0.72mmol)於DMF(5mL)中之溶液。在室溫下振盪混合物4小時,過濾所得樹脂,用DMF(3×6mL)、MeOH(3×6mL)及DCM(3×6mL)洗滌,且真空乾燥。自樹脂裂解少量化合物,藉由LCMS分析,其指示反應完成。所得樹脂用於下一步反應中。LC-MS:785(M+H)。
在室溫下向樹脂中間物31中添加DCM(2mL)及TFA(0.493mL,6.40mmol)。在室溫下振盪混合物20min。用DCM/TFA(1:1,3×2mL)洗滌樹脂,且真空蒸發濾液。藉由逆相HPLC(ACN/H2O 0.1%甲酸,ACN為10%至50%,14min內)純化殘餘物。將純溶離份凍乾,得到呈白色固體狀之(2S,4R)-4-(2-((1R,3R)-1-乙醯氧基-3-((2S,3S)-N-乙基-2-(2-乙基-1-甲基哌啶-2-甲醯胺基)-3-甲基戊醯胺基)-4-甲基戊基)噻唑-4-甲醯胺基)-5-(4-胺基苯基)-2-甲基戊酸(0.057g,20.31%)。LC-MS:785(M+H);1H NMR(400MHz,CD3OD)δ ppm 7.98(s,1 H),6.87(m,J=8.28Hz,2 H),6.54(m,J=8.03Hz,2 H),5.63-5.73(m,1 H),4.60-4.71(m,3H),4.17(br.s.,2 H),3.76(dd,J=14.93,7.15Hz,1
H),2.69(d,J=6.53Hz,2 H),2.42(br.s.,1 H),2.36(s,3 H),2.29(br.s.,2 H),2.03-2.12(m,3 H),1.88(d,J=9.79Hz,3 H),1.79(br.s.,2 H),1.49-1.64(m,5 H),1.43(br.s.,2 H),1.23-1.35(m,4 H),1.11(d,J=7.78Hz,1 H),1.06(d,J=7.03Hz,4 H),0.93(d,J=15.81Hz,3 H),0.94(d,J=15.56Hz,3 H),0.70-0.87(m,9 H)。
向1-(第三丁氧羰基)-2-甲基哌啶-2-甲酸(1g,4.11mmol)及碳酸鉀(0.852g,6.17mmol)於ACN(20mL)中之懸浮液中逐滴添加苯甲基溴(0.733mL,6.17mmol)。在室溫下攪拌所得反應混合物隔夜。LC/MS指示所需產物形成。用水(2mL)稀釋反應混合物且用乙酸乙酯(2×30mL)萃取。合併之萃取物經硫酸鈉乾燥,過濾且濃縮。藉由急驟層析(矽膠,己烷/乙酸乙酯,80/20溶離劑)純化粗物質,產生呈油狀之2-甲基哌啶-1,2-二甲酸2-苯甲酯1-(第三丁基)酯(1.27g,92%)。LC-MS:356(M+Na);1H NMR(400MHz,CD2Cl2)δ ppm 7.33-7.45(m,5 H),5.13-5.27(m,2 H),3.91-4.09(m,1 H),2.83-3.09(m,1 H),2.10-2.32(m,1 H),1.56-1.72(m,1 H),1.30-1.51(m,12 H),1.09(qd,J=12.42,4.64Hz,1 H),0.90-0.98(m,3 H)。
向中間物32(1.2g,3.60mmol)於DCM(10mL)中之溶液中逐滴TFA(4.16mL,53.99mmol)。在室溫下攪拌所得反應混合物2小時。
LC/MS指示Boc完全脫除保護基。減壓移除溶劑。用飽和碳酸氫鈉水溶液鹼化粗物質且用乙酸乙酯(2×50mL)萃取水層。合併之萃取物經硫酸鈉乾燥,過濾且濃縮,得到呈油狀之2-甲基哌啶-2-甲酸苯甲酯(810mg)。粗產物未經純化即用於下一步驟。LC/MS:234(M+1)。
在0℃下向中間物33(1.45g,6.22mmol)及DIEA(2.388mL,13.67mmol)於DCM(25mL)中之溶液中逐滴添加氯甲酸苯甲酯(0.875mL,6.22mmol)。在室溫下攪拌所得溶液2小時。用30mL DCM及4mL飽和碳酸氫鈉溶液水溶液稀釋反應混合物,攪拌5分鐘。分離有機層且用DCM萃取水層(2×30mL)。合併之有機萃取物經硫酸鈉乾燥,過濾且濃縮。藉由急驟層析(矽膠,己烷/乙酸乙酯,90/10)純化粗物質得到呈油狀之2-甲基哌啶-1,2-二甲酸二苯甲酯(1.32g,58%)。LC-MS:268(M+1);1H NMR(400MHz,甲醇-d 4)δ ppm 7.21-7.42(m,10 H),5.04-5.18(m,2 H),5.00(br.s.,2 H),4.91(br.s.,1 H),3.88(d,J=12.80Hz,1 H),3.17(t,J=9.54Hz,1 H),1.83-1.97(m,1 H),1.55-1.78(m,4 H),1.51(s,3 H)。
中間物34經歷兩種對映異構體之SFC對掌性管柱解析(Chiralpak
AD,二氧化碳/甲醇90%-10%)以分離所需產物(R)-2-甲基哌啶-1,2-二甲酸二苯甲酯,LC-MS:368(M+1);1H NMR(400MHz,CD3OD)δ ppm 7.19-7.44(m,10 H),5.04-5.15(m,2 H),5.00(br.s.,2 H),3.88(d,J=13.05Hz,1 H),3.17(t,J=9.54Hz,1 H),1.84-1.97(m,1 H),1.55-1.78(m,5 H),1.51(s,3 H);%ee:>98:旋光度:[α]D:+2°(甲醇)。
向中間物35(600mg,1.63mmol)於甲醇(10mL)中之溶液中添加多聚甲醛(49.0mg,1.63mmol)及鈀/碳(174mg,1.63mmol)。在氫氣氛圍下,在室溫下攪拌反應混合物隔夜。LC/MS指示起始物質完成。過濾反應混合物,用MeOH(2×30mL)洗滌催化劑。真空濃縮濾液得到呈白色固體狀之粗產物,用乙醚(3×30mL)洗滌,高真空乾燥隔夜,產生呈白色固體狀之1,2-二甲基哌啶-2-甲酸(230mg,90%)。LC-MS:158(M+1);1H NMR(400MHz,甲醇-d4)δ ppm 3.03-3.18(m,1 H),2.76(br.s.,3 H),2.01(br.s.,1 H),1.83(br.s.,2 H),1.72-1.81(m,1 H),1.62-1.71(m,2 H),1.48(s,3 H);旋光度:αD +24°(甲醇)。
向樹脂中間物26(0.5g,0.80mmol)中添加中間物36(0.189g,1.20mmol)、HATU(0.608g,1.60mmol)、2,4,6-三甲基吡啶(0.318
mL,2.40mmol)及DIEA(0.419mL,2.40mmol)於DMF(5mL)中之溶液。在室溫下振盪混合物2小時,過濾所得樹脂,用DMF(3×6mL)、MeOH(3×6mL)及DCM(3×6mL)洗滌,且乾燥。自樹脂裂解少量化合物,藉由LC/MS分析,其指示反應完成。所得樹脂用於下一步反應中。LC-MS:801(M+1)。
向樹脂中間物37(0.5g,0.80mmol)中添加氯化錫(II)二水合物(1.384g,6.13mmol)及乙酸鈉(0.151g,1.84mmol)於DMF(5mL)中之溶液。在室溫下振盪混合物4小時,且過濾所得樹脂,用DMF(3×6mL)、MeOH(3×6mL)及DCM(3×6mL)洗滌,且真空乾燥。自樹脂裂解少量化合物,藉由LC/MS分析,其指示反應完成。所得樹脂用於下一步反應中。LC-MS:771(M+H)。
在室溫下向樹脂中間物38(0.15g,0.24mmol)中添加DCM(5mL)及TFA(0.370mL,4.80mmol)。在室溫下振盪混合物10min,接著過濾,且用DCM(2×50mL)洗滌。真空蒸發濾液。藉由逆相HPLC(ACN/H2O 0.1%甲酸,ACN為10%至50%,14min內)純化殘餘物。將純溶離份凍乾,得到呈固體狀之(2S,4R)-4-(2-((1R,3R)-1-乙醯氧基-3-
((2S,3S)-2-((R)-1,2-二甲基哌啶-2-甲醯胺基)-N-乙基-3-甲基戊醯胺基)-4-甲基戊基)噻唑-4-甲醯胺基)-5-(4-胺基苯基)-2-甲基戊酸(0.037g,17.86%)。LC/MS:771(M+1);1H NMR(400MHz,CD3OD)δ ppm 7.97(s,1 H),6.87(d,J=8.03Hz,2 H),6.53(d J=8.03Hz,2 H),5.67(d,J=12.80Hz,1 H),4.59(d,J=8.28Hz,1 H),4.17(br.s.,2 H),3.72(d,J=7.28Hz,1 H),2.69(d,J=6.27Hz,3 H),2.42(br.s.,2 H),2.28(br.s.,2 H),2.17(s,3 H),2.07(s,3 H),1.74-1.94(m,3 H),1.45-1.62(m,4 H),1.36(br.s.,3 H),1.27(t,J=7.03Hz,3 H),1.10(s,3 H),1.06(d,J=7.03Hz,4 H),0.95(d,J=6.53Hz,3 H),0.90(d,J=6.78Hz,4 H),0.83(t,J=7.40Hz,4 H),0.74(d,J=6.27Hz,3 H)。
在0℃下在攪拌下將三乙胺(40g,0.4mol)添加至Boc-L-苯丙胺
酸(90g,0.34mol)及N,O-二甲基羥胺鹽酸鹽(36.5g,0.37mol)於DCM(500mL)中之懸浮液中。攪拌懸浮液10min且添加EDCI(鹽酸鹽,72g,0.37mol)。在0℃下再攪拌懸浮液3小時。用飽和NaHCO3水溶液(1L)淬滅混合物。分離各層,且再用DCM(500mL×3)萃取水相。用水(1L×3)、5%KHSO4水溶液(1L×3)、飽和NaHCO3水溶液(1L×3)及鹽水(1L×1)洗滌合併之有機相,乾燥(Na2SO4)且濃縮至乾燥。粗物質藉由急驟層析(矽膠,EtOAc/己烷=1:1)進一步純化且得到呈白色固體狀之1-(甲氧基(甲基)胺基)-1-側氧基-3-苯基丙-2-基胺基甲酸(S)-第三丁酯(85.1g,產率81%)。1H NMR(300MHz,CDCl3):δ 7.15~7.26(m,5H),5.25(bs,1H),4.95(m,1H),3.63(s,3H),3.14(s,3H),2.83~3.07(m,2H),1.37(s,9H)。
在-10℃下在攪拌下經1小時將中間物39(97.1g,0.315mol)於無水THF(500ml)中之溶液逐滴添加至LiAlH4(12.0g,0.316mol)於無水THF(200mL)中之懸浮液中。在0℃下再攪拌懸浮液3小時,接著在-10℃下用水(12mL)、15%NaOH水溶液(12mL)及水(12mL×3)淬滅。在攪拌0.5小時之後,過濾混合物,濃縮濾液至乾燥,得到1-側氧基-3-苯基丙-2-基胺基甲酸(S)-第三丁酯(45.2g,粗物質),其未經進一步純化即用於下一步驟中。1H NMR(300MHz,CDCl3):δ 9.65(s,1H),7.17~7.33(m,5H),4.80(m,1H),2.80~3.15(m,2H),1.45(s,9H)。
在回流下加熱三苯基膦(173.7g,0.66mol)及2-溴-丙酸乙酯(100g,0.55mol)於乙酸乙酯(400mL)中之溶液隔夜。冷卻後,過濾混合物。用乙酸乙酯洗滌濾餅且乾燥,得到鏻鹽。將鏻鹽溶解於DCM(400mL)中。添加分子篩(4A,50g),隨後在室溫下在攪拌下逐滴添加三乙胺(111g,1.1mol)。再攪拌混合物1小時,接著過濾。用水(300mL×3)、5%KHSO4水溶液(300mL×3)及鹽水(300mL×1)洗滌濾液,乾燥(Na2SO4)且濃縮至乾燥。藉由急驟層析(矽膠,EtOAc/己烷=1:10)進一步純化粗物質且得到呈固體狀之(三苯基膦烯)丙酸乙酯(105g,產率52%)。1H NMR(300MHz,CDCl3):δ 7.34~8.10(m,15H),4.02(q,J=7.2Hz,2H),1.68(m,3H),1.01(t,J=7.2Hz,3H)。
在室溫下攪拌中間物40(52g,0.21mol)及中間物41(76g,0.21mol)於DCM(500ml)中之溶液14小時。減壓移除溶劑。藉由急驟層析(矽膠,EtOAc/己烷=1:10)進一步純化殘餘物且得到呈油狀之4-(t第三丁氧羰基胺基)-2-甲基-5-苯基戊-2-烯酸(S)-乙酯(45.3g,產率64%)。1H NMR(300MHz,CDCl3):δ 7.17~7.32(m,5H),6.53(dd,J=1.2及9Hz,1H),4.63(m,2H),4.18(q,J=7.2Hz,2H),2.76~2.95(m,2H),1.72(s,3H),1.42(s,9H),1.28(t,J=7.2Hz,3H)。
將中間物42(45g,0.135mol)溶解於含有10% Pd/C(10g)之MeOH(600mL)中。在室溫下在氮氣氛圍下攪拌反應混合物16h。經由矽藻土過濾反應混合物且減壓濃縮濾液。將殘餘物溶解於丙酮(200mL)中且在0℃下添加NaOH水溶液(2M,135mL)。在室溫下攪拌混合物10小時。將反應混合物傾入HCl水溶液(2M,135mL)中且用DCM(300mL×3)萃取。乾燥(MgSO4)合併之有機萃取物,過濾且減壓濃縮,得到(R)-4-(第三丁氧羰基胺基)-2-甲基-5-苯基戊酸(41.0g,產率約100%),其未經進一步純化即用於下一步驟。LC-MS確定其結構。
將中間物43(28g,0.091mol)溶解於無水THF(200mL)中且冷卻至-40℃。向此溶液中添加三乙胺(10.1g,0.099mol),隨後經15min逐滴添加氯甲酸乙酯(11g,0.10mol)。在-40℃下再攪拌反應混合物1小時,接著過濾以移除沈澱之物質。使濾液冷卻至0℃且經30min用含有於水(20mL)中之硼氫化鈉(7.5g,0.197mol)之水性懸浮液處理。在0℃下攪拌反應混合物30min,且在室溫下再攪拌30min。用EtOAc(500mL)稀釋混合物且用鹽水(500mL)洗滌。用EtOAc(200mL×3)萃取水層。用飽和NaHCO3水溶液(500mL×2)及鹽水(500ml)洗滌合併之有機萃取物,乾燥(MgSO4),過濾且減壓濃縮以提供油性殘餘物。藉由急驟層析(矽膠,EtOAc/己烷=10:1)純化殘餘物且得到呈油狀之
(2R,4S)-5-羥基-4-甲基-1-苯基戊-2-基胺基甲酸第三丁酯(17.5g,產率65%)。1H NMR(300MHz,CDCl3):δ 7.15~7.29(m,5H),4.60(m,1H),4.00(m,1H),3.45(d,J=5.7Hz,2H),2.71~2.11(m,4H),1.78(m,1H),1.55(m,1H),1.38(s,9H),1.25(m,1H)。
將戴斯-馬丁高碘烷(39g,89.4mmol)添加至中間物44(17.5g,59.7mmol)於DCM(300mL)中之溶液中且在室溫下攪拌懸浮液15小時。用NaOH水溶液(1N,300mL×3)及鹽水(300mL×3)洗滌混合物,乾燥(MgSO4),過濾,且減壓濃縮。藉由急驟層析(矽膠,EtOAc/己烷=1:6)純化殘餘物且得到呈油狀之(3S,5R)-5-苯甲基-3-甲基-2-側氧基吡咯啶-1-甲酸第三丁酯(9.1g,產率53%)。1H NMR(300MHz,CDCl3):δ 7.16~7.35(m,5H),4.30(m,1H),3.15(dd,J=3.3及13.2Hz,1H),2.73(dd,J=9.6及13.2Hz),2.42(m,1H),2.00~2.10(m,2H),1.58(s,9H),1.15(d,J=6.9Hz,3H)。
在回流下加熱中間物45(9.0g,31.1mmol)及HCl水溶液(4N,150mL)4小時。冷卻後,減壓移除溶劑。將殘餘物溶解於丙酮(100mL)及水(100mL)中。用2M NaOH水溶液將溶液之pH值調節至8.5且逐滴添加Fmoc-OSu(12g,35mmol)於丙酮(20mL)中之溶液,在此過
程期間用2M NaOH水溶液將此溶液之pH值維持在8至9。攪拌懸浮液4小時,接著用2M HCl水溶液酸化至pH 3,用EtOAc(200mL×3)萃取。用水(100mL×3)、5% KHSO4水溶液(100mL×3)及鹽水(100mL×1)洗滌合併之有機層,乾燥(Na2SO4)且濃縮至乾燥。藉由急驟層析(矽膠,EtOAc/己烷=1:1)純化粗物質且得到(2S,4R)-4-氟基((((9H-茀-9-基)甲氧基)羰基)胺基)-2-甲基-5-苯基戊酸(5.3g,產率40%)。LC-MS:430[M+1];1H NMR(400MHz,甲醇-d4)δ ppm 7.78-7.83(m,2 H),7.59-7.65(m,2 H),7.37-7.43(m,2 H),7.28-7.35(m,2 H),7.14-7.26(m,5 H),6.94-7.01(m,1 H),4.28-4.36(m,1 H),4.21-4.27(m,1 H),4.10-4.16(m,1 H),3.84-3.93(m,1 H),2.68-2.82(m,2 H),2.48-2.60(m,1 H),1.86-1.95(m,1 H),1.42-1.51(m,1 H),1.17(d,J=7.03Hz,3 H),1.09-1.14(m,1 H)。
在-20℃下經15min將氯甲酸乙酯(12.6mL,0.13mol)逐滴添加至I-Me-Boc-L-Val-OH(27.3g,0.12mol)及三乙胺(14.7mL,0.13mol)於無水THF(200mL)中之溶液中,且再攪拌所得白色懸浮液30min。接著經由插管將重氮甲烷(0.36mol,由60g N-亞硝基-N-甲基脲製備且經氫氧化鉀乾燥)於乙醚(500mL)中之溶液引入至反應混合物中。使混合物升溫至室溫且再攪拌5小時,接著用乙酸水溶液(10%,250mL)小心淬滅。分離各層,且用飽和碳酸氫鈉(300mL×3)及鹽水(300mL×3)洗滌有機層,乾燥(Na2SO4),濃縮至約200mL。將殘餘物溶解於THF(900mL)及水(100mL)中。將溶液加熱至40℃,且添加乙酸銀(500mg)。攪拌懸浮液5小時,接著濃縮至約300mL。用EtOAc(500mL×3)萃取殘餘物。用飽和碳酸氫鈉(300mL×3)及鹽水(300mL)洗滌有機層,乾燥(Na2SO4),濃縮,得到(R)-3-(第三丁氧羰基(甲基)胺基)-4-甲基戊酸(23.8g,產率81%),其未經進一步純化即用於下一步驟。1H NMR(300MHz,CDCl3):δ 10.08(bs,1H),4.00(m,1H),2.75(m,3H),2.55(m,2H),1.43(s,9h),0.85~0.84(m,6H)。
在0℃下在攪拌下將三乙胺(34.3mL,0.244mol)添加至中間物47(60g,0.244mol)及N,O-二甲基羥胺鹽酸鹽(23.9g,0.244mol)於CH2Cl2(300mL)中之懸浮液中。在此溫度下攪拌懸浮液0.5小時,接著在0℃下逐份添加EDCI(46.9g,0.244mol)。在0℃下再攪拌反應混合物2小時,接著用水(300mL)淬滅。分離有機相,且用5% KHSO4水
溶液(300mL×3)、飽和NaHCO3水溶液(300mL×3)及鹽水(300mL×1)洗滌,乾燥(Na2SO4)且濃縮至乾燥。藉由矽膠層析(EtOAc/己烷=1:3)進一步純化殘餘物且得到呈油狀之(R)-(1-(甲氧基(甲基)胺基)-4-甲基-1-側氧基戊-3-基)(甲基)胺基甲酸第三丁酯(52g,產率74%)。
在0℃下經1小時之時段將亞硝酸第三丁酯(自0.61mol NaNO2及110mL第三丁醇製備)逐滴添加至CuBr2(260g,1.16mol)及2-胺基噻唑-4-甲酸乙酯(100g,0.58mol)於ACN(500mL)中之懸浮液中。在室溫下攪拌混合物12小時,接著用EtOAc(800mL)及水(800mL)淬滅。過濾混合物,且將濾液分成水相及有機相。用EtOAc(800mL×2)萃取水相。用5% KHSO4水溶液(300mL×3)、飽和NaHCO3水溶液(300mL×3)及鹽水(300mL×1)洗滌合併之有機萃取物,乾燥(Na2SO4)且濃縮至乾燥,得到2-溴噻唑-4-甲酸乙酯(79.4g,產率58%),其未經進一步純化即用於下一步驟。1H NMR(300MHz,DMSO-d6):δ 7.45(s,1H),4.20(q,J=7.2Hz,2H),1.25(t,J=7.2Hz,3H)。
在50℃下在攪拌下經0.5小時之時段將NaBH4(16.5g,0.43mol)逐份添加至中間物49(68g,0.288mol)於乙醇(500mL)中之溶液中。在回流下加熱懸浮液5小時,且分批添加另一批NaBH4(8.25g,0.22mol)。在回流下再加熱混合物12小時。在冷卻至室溫之後,減壓移除溶劑,且將殘餘物溶解於DCM(500mL)中,且用飽和NaHCO3水溶液
(300mL×3)及鹽水(300mL×1)洗滌,乾燥(Na2SO4)且濃縮至乾燥,得到醇。將醇溶解於DMF(300mL)中且添加咪唑(28.3g,0.416mol)。在室溫下將TBS-Cl(62.4g,0.416mol)於THF(100mL)中之溶液逐滴添加至此溶液中。攪拌混合物12小時,接著用水(800mL)淬滅且用EtOAc(800mL×2)萃取。用5% KHSO4水溶液(300mL×3)、飽和NaHCO3水溶液(300mL×3)及鹽水(300mL×1)洗滌合併之有機萃取物,乾燥(Na2SO4)且濃縮至乾燥。藉由急驟層析(矽膠,EtOAc/己烷=1:30)純化殘餘物且得到呈油狀之2-溴-4-((第三丁基二甲基矽烷氧基)甲基)噻唑(42.0g,產率47%,兩個步驟)。1H NMR(300MHz,CDCl3):δ 7.15(t,J=1.5Hz,1H),4.84(d,J=1.5Hz,2H),0.94 9s,9H),0.12(s,6H)。
在-78℃下,在N2下,在攪拌下,經1小時將n-BuLi之溶液(77mL,2.5N己烷溶液,0.19mol)逐滴添加至中間物50(53.9g,0.175mol)於無水THF(500mL)中之溶液中。在此溫度下攪拌懸浮液30min。接著在-78℃下經30min逐滴添加中間物48(50.4g,0.175mol)於無水THF(200mL)中之溶液。在此溫度下攪拌反應混合物1小時,接著升溫至室溫且攪拌12小時。用20%氯化銨水溶液(1L)淬滅混合物且減壓移除有機溶劑。用EtOAc(500mL×3)萃取所得混合物。用5% KHSO4水溶液(500mL×3)、飽和NaHCO3水溶液(500mL×3)及鹽水(500mL×1)洗滌合併之有機萃取物,乾燥(Na2SO4)且濃縮至乾燥。藉由急驟層析(矽膠,EtOAc/己烷=1:10)進一步純化粗物質且得到呈油狀之1-(4-((第三丁基二甲基矽烷氧基)甲基)噻唑-2-基)-4-甲基-1-側氧基
戊-3-基(甲基)胺基甲酸(R)-第三丁酯(38.1g,產率48%)。1H NMR(300MHz,CDCl3):δ 7.55(m,1H),4.91(s,2H),4.27(m,1H),3.20~3.60(m,2H),1.90(m,1H),1.03(d,J=6.6Hz,3H),0.97(s,9H),0.88(d,J=6.6Hz,3H),0.15(s,6H)。
在室溫下在攪拌下經0.5小時之時段將NaBH4(4.7g,125mmol)逐份添加至中間物51(38.0g,83.3mmol)於甲醇(200mL)中之溶液中。攪拌懸浮液2小時,且再添加一批NaBH4(1.5g,40mmol)且再攪拌混合物2小時。減壓移除溶劑,且將殘餘物溶解於EtOAc(200mL)中,用飽和NaHCO3水溶液(200mL×3)及鹽水(200mL×1)洗滌,乾燥(Na2SO4)且濃縮至乾燥。藉由矽膠層析(EtOAc/己烷=1:6)進一步純化粗物質且得到(1R,3R)-1-(4-((第三丁基二甲基矽烷氧基)甲基)噻唑-2-基)-1-羥基-4-甲基戊-3-基(甲基)胺基甲酸第三丁酯(16.2g,產率42%)及((1S,3R)-1-(4-(((第三丁基二甲基矽烷基)氧基)甲基)噻唑-2-基)-1-羥基-4-甲基戊-3-基)(甲基)胺基甲酸第三丁酯(異構體,17.3g,產率45%)。
(1R,3R)-1-(4-((第三丁基二甲基矽烷氧基)甲基)噻唑-2-基)-1-羥基-4-甲基戊-3-基(甲基)胺基甲酸第三丁酯(1R,3R-異構體):1H NMR(300MHz,CDCl3):δ 7.11(s,1H),4.98(bs,1H),4.80(s,2H),4.68(dt,J=11.7Hz,1H),3.95(dt,J=3.3與12Hz,1H),2.75(s,3H),1.70~1.95(m,2H),1.49(s,9H),0.95(s,9H),0.85~0.95(m,6H),0.15(s,6H)。
((1S,3R)-1-(4-(((第三丁基二甲基矽烷基)氧基)甲基)噻唑-2-基)-1-羥基-4-甲基戊-3-基)(甲基)胺基甲酸第三丁酯(1S,3R-異構體):1H
NMR(300MHz,CDCl3):δ 7.07(s,1H),5.01(m,1H),4.81(s,2H),4.81(bs,1H),3.86(dt,J=3.3與10.5Hz,1H),2.35(s,3H),2.25(m,1H),1.74(m,1H),1.43(s,9H),1.00(d,J=6.6Hz,3H),0.96(s,9H),0.84(d,J=6.6Hz,3H),0.15(s,6H)。
在0℃下,在攪拌下,經1小時將乙醯氯(22.5mL,0.316mol)逐滴添加至中間物52(19.7g,43mmol)於吡啶(140mL)中之溶液中。使反應混合物升溫至室溫且攪拌12小時。用水(200mL)淬滅混合物且減壓移除有機溶劑。將殘餘物溶解於DCM(500ml)中且用5% KHSO4水溶液(200mL×3)、飽和NaHCO3水溶液(200mL×3)及鹽水(200mL×1)洗滌,乾燥(Na2SO4)且濃縮至乾燥。藉由急驟層析(矽膠,EtOAc/己烷=1:10)純化粗物質且得到呈油狀之乙酸(1R,3R)-3-(第三丁氧羰基(甲基)胺基)-1-(4-((第三丁基二甲基矽烷氧基)甲基)噻唑-2-基)-4-甲基戊酯(18.5g,產率86%)。LC-MS確定其結構。
在0℃下在攪拌下將氟化四丁基銨(45.7g,175mmol)於THF(100mL)中之溶液逐滴添加至中間物53(17.5g,35mmol)於THF(100mL)中之溶液中。使反應混合物升溫至室溫且攪拌12小時。用水(100mL)淬滅混合物且減壓移除有機溶劑。將殘餘物溶解於CH2Cl2(500ml)中
且用5% KHSO4水溶液(200mL×3)、飽和NaHCO3水溶液(200mL×3)及鹽水(200mL×1)洗滌,乾燥(Na2SO4)且濃縮至乾燥。藉由急驟層析(矽膠,EtOAc/己烷=1:4)純化粗物質且得到呈油狀之乙酸(1R,3R)-3-(第三丁氧羰基(甲基)胺基)-1-(4-(羥基甲基)噻唑-2-基)-4-甲基戊酯(9.3g,產率69%)。1H NMR(300MHz,CDCl3):δ 7.15(d,J=3Hz,1H),5.81~5.86(m,1H),4.74(d,J=3Hz,2H),4.11(m,1H),2.70與2.63(s,3H),2.31(m,1H),2.15(s,3H),2.05(m,1H),1.70(m,1H),1.47(s,9H),0.98(d,J=6.6Hz,3H),0.86(d,J=6.6Hz,3H)。
將戴斯-馬丁高碘烷(14.9g,34.2mmol)添加至中間物54(8.8g,22.8mmol)於二氯甲烷(250mL)中之溶液中。在室溫下攪拌反應混合物12小時,接著用氫氧化鈉水溶液(1N,200mL×3)、硫代硫酸鈉水溶液(1N,200mL×3)、飽和NaHCO3水溶液(200mL×3)及鹽水(200mL×1)洗滌,乾燥(Na2SO4)且濃縮至乾燥,得到醛。
將此粗醛溶解於第三丁醇(250ml)中且在室溫下經1小時逐滴添加亞氯酸鈉(80%,11.6g,102mmol)及磷酸二氫鈉單水合物(33.6g,244mol)於水(150mL)中之溶液。再攪拌反應混合物16h,接著用鹽酸(0.1N,100mL)稀釋且用EtOAc(200mL×3)萃取。用5% KHSO4水溶液(200mL×3)及鹽水(200mL×1)洗滌合併之有機層,乾燥(Na2SO4)且濃縮至乾燥,得到2-((1R,3R)-1-乙醯氧基-3-(第三丁氧羰基(甲基)胺基)-4-甲基戊基)噻唑-4-甲酸(7.5g,產率82%),其未經進一步純化即用於下一步驟。1H NMR(300MHz,CDCl3):δ 8.26(s,1H),5.87~6.01
(m,1H),4.15(m,1H),2.72與2.65(s,3H),2.35(m,1H),2.20(s,3H),2.18(m,1H),1.75(m,1H),1.49(s,9H),1.00(d,J=6.6Hz,3H),0.88(d,J=6.6Hz,3H)。
將TFA(30mL)添加至中間物55(7.4g,18.5mmol)於二氯甲烷(80mL)中之溶液中。攪拌混合物12小時,且減壓移除溶劑。將殘餘物溶解於丙酮(100mL)及水(100mL)中。用2M NaOH水溶液將溶液之pH值調節至8.5且逐滴添加Fmoc-OSu(6.2g,18.5mmol)於丙酮(50mL)中之溶液,在此過程期間用2M NaOH水溶液將此溶液之pH值維持在8至9。攪拌懸浮液4小時,用2M HCl水溶液酸化至pH 3,用EtOAc(200mL×3)萃取。用水(100mL×3)、5% KHSO4水溶液(100mL×3)及鹽水(100mL×1)洗滌合併之有機層,乾燥(Na2SO4)且濃縮至乾燥。藉由急驟層析(矽膠,MeOH/CH2Cl2=1:40)純化粗物質且得到2-((1R,3R)-3-((((9H-茀-9-基)甲氧基)羰基)(甲基)胺基)-1-乙醯氧基-4-甲基戊基)噻唑-4-甲酸(5.1g,產率53%)。LC-MS:523[M+1];1H NMR(400MHz,CDCl3)δ ppm 0.56(br.s.,1 H)0.67-0.82(m,2 H)0.83-0.96(m,2 H)1.64(dt,J=10.36,6.57Hz,1 H)1.88(s,1 H)2.07(s,2 H)2.09-2.17(m,1 H)2.19-2.33(m,1 H)2.52-2.67(m,3 H)3.86-4.01(m,1 H)4.08(s,1 H)4.12-4.21(m,1 H)4.29-4.40(m,1 H)4.68(dd,J=10.61,5.56Hz,1 H)5.85(dd,J=10.86,3.28Hz,1 H)7.19-7.27(m,2 H)7.27-7.35(m,2 H)7.42-7.58(m,2 H)7.61-7.71(m,2 H)8.11-8.19(m,1 H)。
將DIEA(0.419mL,2.40mmol)添加至中間物46(0.344g,0.80mmol)於DCM(1.5mL)中之溶液中,且在室溫下攪拌混合物5min,接著將2-氯三苯甲基氯樹脂(0.5g,0.80mmol)添加至混合物中。在室溫下振盪混合物4小時,用DMF(3×6mL)、MeOH(3×6mL)及DCM(3×6mL)洗滌所得樹脂,接著在室溫下用DIEA(0.419mL,2.40mmol)及MeOH/DCM(1:1,5mL)處理30min。過濾所得樹脂,用DMF(3×6mL)、MeOH(3×6mL)及DCM(3×6mL)洗滌,高真空乾燥隔夜。自樹脂裂解少量化台物且藉由LCMS分析。乾燥之樹脂用於下一步驟中。LC-MS:430(M+1)。
向樹脂中間物57(0.5g,0.80mmol)中添加含20%哌啶之DMF(5mL)。在室溫下振盪混合物6min,過濾所得樹脂,用DMF(3×6mL)、MeOH(3×6mL)、DCM(3×6mL)洗滌,真空乾燥。自樹脂裂解少量化合物,藉由LC/MS分析,其指示反應完成。所得樹脂用於下一步反應中。LC-MS:208(M+1)。
向樹脂中間物58(0.4g,0.64mmol)中添加中間物56(0.351g,0.67mmol)、HATU(0.487g,1.28mmol)、2,4,6-三甲基吡啶(0.256mL,1.92mmol)及DIEA(0.335mL,1.92mmol)於DMP(4mL)中之溶液。在室溫下振盪混合物2小時。過濾所得樹脂,用DMF(3×6mL)、MeOH(3×6mL)及DCM(3×6mL)洗滌,真空乾燥。自樹脂裂解少量化合物且藉由LCMS分析。反應完成。所得樹脂用於下一步反應中。LC-MS:712(M+1)。
向樹脂中間物59(0.4g,0.64mmol)中添加含20%哌啶之DMF(4mL)。在室溫下振盪混合物6min,過濾所得樹脂,用DMF(3×6mL)、MeOH(3×6mL)、DCM(3×6mL)洗滌,真空乾燥。自樹脂裂解少量化合物,藉由LCMS分析,其指示反應完成。所得樹脂用於下一步反應中。LC/MS:491(M+H)。
在室溫下向樹脂中間物60(0.4g,0.64mmol)中添加中間物24(0.341g,0.96mmol)、DMAP(3.91mg,0.03mmol)及DIEA(0.335mL,1.92mmol)於DCM(4mL)中之溶液。在室溫下振盪混合物1小時,過濾所得樹脂,用DMF(3×6mL)、MeOH(3×6mL)、DCM(3×6mL)洗滌,高真空乾燥。自樹脂裂解少量化合物且藉由LCMS分析。
所得樹脂用於下一步驟中。LC-MS:825(M+1)。
向樹脂中間物61(0.4g,0.64mmol)中添加含20%哌啶之DMF(4mL)。在室溫下振盪混合物6min,過濾所得樹脂,用DMF(3×6mL)、MeOH(3×6mL)、DCM(3×6mL)洗滌,真空乾燥。自樹脂裂解少量化合物,藉由LCMS分析,其指示反應完成。所得樹脂用於下一步反應中。LC-MS:603(M+1)。
在回流下加熱4,4-二甲基環己酮(30g,0.238mol)、羥胺鹽酸鹽(32.8g,0.476mol)及乙酸鈉(39.0g,0.476mol)於H2O/EtOH(720mL,5/1)中之溶液。藉由TLC監測反應且在完成時冷卻至室溫。用二氯甲烷(500ml)稀釋。分離有機層,用鹽水(100mL)洗滌且經Na2SO4乾燥。減壓移除溶劑,且獲得呈無色固體狀之4,4-二甲基環己酮,其
未經進一步純化即用於下一步驟。
經20分鐘向五氯化磷(120g,0.576mol)於二甲苯(1000mL)中之攪拌漿料中添加中間物63(27.2g,0.192mol)於二甲苯(400mL)中之溶液。在添加期間使用水浴使反應混合物維持於30至36℃下。接著加熱至80℃且攪拌1.5小時。使均勻反應混合物冷卻至室溫且傾入飽和碳酸鈉水溶液(2000mL)中。使混合物靜置隔夜且收集沈澱。呈棕色固體狀之3,3-二氯-5,5-二甲基氮雜環庚-2-酮(28.4g)且未經進一步純化即用於下一步驟。1H NMR(300MHz,CDCl3):δ 6.51(bs,1H),3.39-3.44(m,1H),3.16-3.21(m,1H),1.41-1.51(m,2H),1.17(s,2H),0.99(s,6H)。
將中間物64(25.8,0.123mol)溶解於冰醋酸(1300mL)中且在室溫下在40大氣壓之氫氣下經Pd/C(13g,10%)攪拌2h。濾出催化劑且真空濃縮濾液。將DCM(200mL)及飽和NaHCO3水溶液(200mL)添加至殘餘物中且攪拌混合物10min。分離有機層,經Na2SO4乾燥且真空濃縮,得到3-氯-5,5-二甲基氮雜環庚-2-酮(19.1g),其未經進一步純化即用於下一步驟。1H NMR(300MHz,CDCl3):δ 6.19(brs,1H),4.75(d,J=11Hz,1H),3.30-3.36(m,1H),3.11-3.17(m,1H),1.91-2.09(m,2H),1.39-1.59(m,2H),1.14(s,3H),1.04(s,3H)。
向裝入中間物65(16.1g,0.092mol)及Ba(OH)2(35.1g,0.11mol)之燒瓶中添加水(400mL)。在110℃下攪拌此混合物2h。接著冷卻至室溫,且添加CBZ氯化物(20.6g,0.121mol)於THF(400mL)中之溶液。在室溫下攪拌混合物隔夜,接著使用1N HCl調節至pH 3。用乙酸乙酯(2×200mL)萃取粗產物。用鹽水(100mL)洗滌合併之萃取物,經Na2SO4乾燥且減壓濃縮。藉由矽膠層析純化殘餘物得到呈黏稠油狀之1-((苯甲氧基)羰基)-4,4-二甲基哌啶-2-甲酸(7g)。1H NMR(300MHz,CDCl3):δ 7.33-7.38(m,5H),5.16-5.19(m,2H),4.78-4.88(m,1H),3.95-3.99(m,1H),3.23-3.27(m,1H),2.07(s,2H),1.64-1.71(m,1H),1.37-1.40(m,2H),0.97(s,3H),0.93(s,3H)。
藉由chiralpak IC使用移動相A 90%二氧化碳/移動相B 10%乙醇(在210nm下偵測)分離兩種對映異構體。
(R)-1-((苯甲氧基)羰基)-4,4-二甲基哌啶-2-甲酸:LC-MS:292[M+1];1H NMR(400MHz,氯仿-d)δ ppm 0.93(s,3 H)0.98(s,3 H)1.40(d,J=11.80Hz,2 H)1.68(dd,J=14.05,7.28Hz,1 H)1.99-2.18(m,1 H)3.27(m,J=12.30Hz,1 H)3.97(m,J=12.80Hz,1 H)4.69-4.95(m,1 H)5.11-5.25(m,2 H)7.28-7.44(m,5 H)9.63(br.s,1
H)。
向中間物67(1.14g,3.91mmol)於MeOH(20mL)及水(20.00mL)中之溶液中添加多聚甲醛(0.705g,7.83mmol)及Pd/C(10%)(0.4g,3.76mmol)。在氫氣氛圍下,在室溫下攪拌反應混合物隔夜。由TLC,反應完成。再添加多聚甲醛(0.705g,7.83mmol)且在室溫下在氫氣氛圍下攪拌反應混合物隔夜。TLC指示反應完成。過濾反應混合物,用MeOH(2×20mL)洗滌催化劑。真空濃縮濾液得到呈白色固體狀之粗產物,用乙醚(3×20mL)洗滌,高真空乾燥隔夜,產生呈白色固體狀之(R)-1,4,4-三甲基哌啶-2-甲酸(0.671g,100%)。LC-MS:172[M+1];1H NMR(400MHz,D2O)δ ppm 0.96(s,3 H)1.01(s,3 H)1.49-1.63(m,3 H)1.83(dt,J=14.56,2.64Hz,1 H)2.79(s,3 H)3.08-3.18(m,1 H)3.27-3.34(m,1 H)3.54(dd,J=12.80,3.26Hz,1 H)。
向樹脂中間物62(0.1g,0.16mmol)中添加中間物68(0.055g,0.32mmol)、HATU(0.122g,0.32mmol)、2,4,6-三甲基吡啶(0.064mL,0.48mmol)及DIEA(0.056mL,0.32mmol)於DMF(1mL)中之溶液。在室溫下振盪混合物2小時,過濾所得樹脂,用DMF(3×2mL)、MeOH(3×2mL)及DCM(3×2mL)洗滌,真空乾燥。自樹脂裂解少量化合物,藉由LCMS分析,其指示反應完成。所得樹脂用於下一步驟中。LC-MS:756(M+1)。
向樹脂中間物69(0.1g,0.13mmol)中添加DCM(1mL)及TFA(1mL)。在室溫下振盪混合物20min,接著過濾,用DMF/TFA(1:1,3×2mL)洗滌樹脂,真空蒸發濾液。藉由逆相HPLC(ACN/H2O 0.1% TFA,ACN為5%至75%,14min內)純化殘餘物。將純溶離份凍乾,得到呈白色固體狀之(2S,4R)-4-氟基(2-((1R,3R)-1-乙醯氧基-3-((2S,3S)-N,3-二甲基-2-((R)-1,4,4-三甲基哌啶-2-甲醯胺基)戊醯胺基)-4-甲基戊基)噻唑-4-甲醯胺基)-2-甲基-5-苯基戊酸(30mg,產率30%)。LC-MS:756.5[M+1];1H NMR(400MHz,甲醇-d 4)δ ppm 0.75(dd,J=6.53,2.01Hz,3 H),0.85(td,J=7.34,3.64Hz,4 H),0.90-0.99(m,11 H),1.01-1.16(m,9 H),1.45-1.66(m,6 H),1.67-1.85(m,4 H),1.86-1.97(m,1 H),2.03-2.06(m,3 H),2.16-2.34(m,2 H),2.39-2.51(m,1 H),2.66(d,J=1.25Hz,3 H),2.75-2.85(m,2 H),3.02(d,J=1.25Hz,3 H),3.16(br.s.,1 H),3.79-3.93(m,1 H),4.29(br.s.,2 H),4.57-4.66(m,1 H),5.55-5.70(m,1 H),7.01-7.18(m,5 H),7.98(d,J=1.25Hz,1 H)。
向樹脂中間物62(0.1g,0.16mmol)中添加中間物1(0.050g,0.32mmol)、HATU(0.122g,0.32mmol)、2,4,6-三甲基吡啶(0.064mL,0.48mmol)及DIEA(0.056mL,0.32mmol)於DMF(1mL)中之溶
液。在室溫下振盪混合物2小時,過濾所得樹脂,用DMF(3×2mL)、MeOH(3×2mL)及DCM(3×2mL)洗滌,真空乾燥。自樹脂裂解少量化合物,藉由LCMS分析,其指示反應完成。所得樹脂用於下一步驟中。LC-MS:742(M+1)。
向樹脂中間物70(0.1g,0.16mmol)中添加DCM(1mL)及TFA(1mL)。在室溫下振盪混合物20min,接著過濾,用DMF/TFA(1:1,3×2mL)洗滌樹脂,真空蒸發濾液。藉由逆相HPLC(ACN/H2O 0.1% TFA,ACN為5%至50%,14min內)純化殘餘物。將純溶離份凍乾,得到呈白色固體狀之(2S,4R)-4-氟基(2-((1R,3R)-1-乙醯氧基-3-((2S,3S)-2-((2R,4R)-1,4-二甲基哌啶-2-甲醯胺基)-N,3-二甲基戊醯胺基)-4-甲基戊基)噻唑-4-甲醯胺基)-2-甲基-5-苯基戊酸(0.040g,29.2%)。LC-MS:742(M+1);1H NMR(400MHz,CD3OD)δ ppm 0.71-0.78(m,3 H),0.80-0.87(m,3 H),0.93(dd,J=9.91,6.65Hz,6 H),1.07(d,J=7.03Hz,6 H),1.42-1.65(m,3 H),1.74-1.85(m,3 H),1.86-1.98(m,3 H),2.05(s,4 H),2.16-2.35(m,2 H),2.38-2.51(m,1 H),2.59-2.72(m,3 H),2.77-2.83(m,2 H),3.02(s,3 H),3.84-3.94(m,1 H),4.20-4.35(m,2 H),4.56-4.65(m,1 H),5.57-5.67(m,1 H),7.03-7.09(m,1 H),7.13(s,4 H),7.91-8.02(m,2 H)。
在攪拌下向2-((1R,3R)-3-((2S,3S)-2-(第三丁氧羰基胺基)-N,3-
二甲基戊醯胺基)-1-羥基-4-甲基戊基)噻唑-4-甲酸乙酯(如Patterson A.等人J.Org.Chem. 2008,73,4362中所述製備)(1.2g,2.40mmol)於DCM(24mL)中之溶液中添加等體積之TFA(24.00mL)1h。接著濃縮溶液,用EtOAc稀釋,且用飽和NaHCO3(水溶液)洗滌一次。用EtOAc反萃取溶離份水溶液兩次,且合併之有機溶離份經Na2SO4乾燥,過濾且濃縮,得到脫除Boc保護基之游離胺,其未經進一步純化即可用於下一步驟。向此含胺之CH2Cl2(24mL)中添加HOBT(0.368g,2.40mmol)及中間物1(0.3969g,2.52mmol)。接著在加鹽冰-水浴中在攪拌下冷卻混合物,且添加PS-碳化二亞胺(1.23mmol/g)(2.598g,2.88mmol)。使浴液升溫至室溫且持續攪拌14h。接著過濾混合物,用DCM洗滌樹脂且濃縮濾液。接著用EtOAc稀釋粗混合物且用飽和NaHCO3水溶液洗滌一次。用EtOAc反萃取溶離份水溶液兩次,且合併之有機溶離份經Na2SO4乾燥,過濾且濃縮,得到4-MethylMep-偶合之中間物,其未經進一步純化即可使用。向用二噁烷(24mL)稀釋之粗中間物中添加LiOH(0.230g,9.60mmol)於脫氣水(24mL)中之溶液。攪拌5h之後,濃縮溶液。藉由矽膠管柱用DCM/DCM:MeOH:NH4OH(90:10:1至70:30:1)(DCM:MeOH:NH4OH,以0至100%之梯度)藉由使用正相急驟層析溶離來純化殘餘物。濃縮純溶離份且最終高真空乾燥,得到呈非晶形固體狀之2-((1R,3R)-3-((2S,3S)-2-((2R,4R)-1,4-二甲基哌啶-2-甲醯胺基)-N,3-二甲基戊醯胺基)-1-羥基-4-甲基戊基)噻唑-4-甲酸(1.003g,82%)。LC-MS:509[M+1]。
在冰-水浴中冷卻中間物71(1.0026g,1.96mmol)於吡啶(19.47mL)中之溶液中,且在攪拌下添加乙酸酐(0.927mL,9.82mmol)。使浴液升溫至室溫,且持續攪拌24h。接著在冰-水浴中冷卻溶液,且添加脫氣水/二噁烷之1:1(v/v)溶液(40mL)。使浴液升溫至室溫,且持續攪拌22h。藉由蒸發濃縮殘餘物且藉由逆相層析使用ACN/H2O(0.1%TFA),ACN為5%至50%,在14分鐘內純化殘餘物,使純溶離份凍乾,得到呈無色固體狀之2-((1R,3R)-1-乙醯氧基-3-((2S,3S)-2-((2R,4R)-1,4-二甲基哌啶-2-甲醯胺基)-N,3-二甲基戊醯胺基)-4-甲基戊基)噻唑-4-甲酸(0.945g,72.2%)。LC-MS:551[M+1];1H NMR(400MHz,甲醇-d 4)δ ppm 0.85(d,J=6.53Hz,3 H),0.88-0.98(m,4 H),0.98-1.08(m,6 H),1.10-1.28(m,4 H),1.59(ddd,J=13.49,7.47,2.89Hz,1 H),1.70(d,J=14.05Hz,1 H),1.81-2.12(m,5 H),2.12-2.25(m,3 H),2.32(d,J=7.78Hz,2 H),2.72-2.93(m,4 H),3.07-3.18(m,4 H),4.02(d,J=10.54Hz,1 H),4.10-4.39(m,1 H),4.65-4.76(m,1 H),5.64-5.80(m,1 H),8.30-8.39(m,1 H),8.66(d,J=7.28Hz,1 H)。
在0℃下將中間物72(100mg,0.18mmol)添加至2,3,4,5,6-五氟苯酚(49.32mg,0.27mmol)及DIC(41.34μl,0.27mmol)於DCM(5mL)中之溶液中。使溶液達到室溫,攪拌4小時,接著真空移除溶劑。將EtOAc(4mL)添加至混合物中且抽吸過濾所得懸浮液,在濾液中得到所需活化酸。真空移除EtOAc,接著依序添加無水DMF(1.3mL)、中間物18(52.2mg,0.18mmol)及DIEA(0.213mL)。攪拌混合物隔夜,
接著高真空移除DMF。藉由逆相層析(具有10mM乙酸銨之ACN/H2O,ACN為10%至80%,在20分鐘內)純化殘餘物,且使純溶離份凍乾,得到呈無色固體狀之(2S,4R)-4-氟基(2-((1R,3R)-1-乙醯氧基-3-((2S,3S)-2-((2R,4R)-1,4-二甲基哌啶-2-甲醯胺基)-N,3-二甲基戊醯胺基)-4-甲基戊基)噻唑-4-甲醯胺基)-2-甲基-5-(4-硝基苯基)戊酸(85mg,59.3%)。LC-MS:787[M+1]
25mL圓底燒瓶中裝入攪拌棒且在氮氣下添加中間物73(84.5mg,0.11mmol)及MeOH(5mL)、Pd-C10%(50mg,0.47mmol)。在室溫下使用氫氣球將混合物氫化1小時。粗物質LC/MS展示起始物質完全轉化成產物。經由矽藻土襯墊過濾反應混合物,且經過濾器用MeOH洗滌。減壓濃縮濾液且最終高真空乾燥,得到呈固體狀之(2S,4R)-4-氟基(2-((1R,3R)-1-乙醯氧基-3-((2S,3S)-2-((2R,4R)-1,4-二甲基哌啶-2-甲醯胺基)-N,3-二甲基戊醯胺基)-4-甲基戊基)噻唑-4-甲醯胺基)-5-(4-胺基苯基)-2-甲基戊酸(79mg,97%)。LC-MS:757[M+1];1H NMR(400MHz,甲醇-d 4)δ ppm 8.10(s,1 H)6.99(d,J=8.28Hz,2 H)6.65(d,J=8.28Hz,2 H)5.66-5.78(m,1 H)4.71-4.80(m,1H)4.24-4.43(m,2 H)3.13(s,3 H)2.77-2.83(m,2 H)2.61-2.71(m,1 H)2.49-2.56(m,1 H)2.44(s,3 H)2.27-2.40(m,2 H)2.17(s,3 H)1.86-2.04(m,4 H)1.74-1.83(m,1 H)1.53-1.69(m,3 H)1.31(br.s.,3H)1.17(d,J=7.03Hz,4H)0.98-1.07(m,8 H)0.93(d,J=7.53Hz,6H)0.83-0.87(m,3 H)。
向樹脂中間物28(0.2g,0.32mmol)中添加(S)-2-(((9H-茀-9-基)甲氧基)羰胺基)-6-(第三丁氧羰基胺基)己酸(0.300g,0.64mmol)、HATU(0.243g,0.64mmol)、2,4,6-三甲基吡啶(0.128mL,0.96mmol)及DIEA(0.168mL,0.96mmol)於DMF(4mL)中之溶液。在室溫下振盪混合物2小時,過濾所得樹脂,用DMF(3×2mL)、MeOH(3×2mL)及DCM(3×2mL)洗滌,且真空乾燥。自樹脂裂解少量化合物,藉由LCMS分析,其指示反應完成。所得樹脂中間物74用於下一步反應
中。LC-MS:1221(M+1)。
向樹脂中間物74(0.2g,0.32mmol)中添加含20%哌啶之DMF(2mL)。在室溫下振盪混合物6min,過濾所得樹脂,用DMF(3×3mL)、MeOH(3×3mL)、DCM(3×3mL)洗滌,真空乾燥。自樹脂裂解少量化合物,藉由LCMS分析,其指示反應完成。所得樹脂中間物75用於下一步反應中。LC/MS:999(M+H)。
在室溫下向樹脂中間物75(0.2g,0.32mmol)中依序添加6-(2,5-二側氧基-2,5-二氫-1H-吡咯-1-基)己酸2,5-二側氧基吡咯啶-1-基酯(0.148g,0.48mmol)於DMF(2mL)中之溶液、N-甲基嗎啉(0.106mL,0.96mmol)。在室溫下振盪混合物2小時,過濾所得樹脂,用DMF(3×3mL)、DCM(3×3mL)洗滌,真空乾燥。自樹脂裂解少量化合物,藉由LCMS分析,其指示反應完成。所得樹脂中間物76用於下一步驟中。LC-MS:1192(M+1)。
在室溫下向樹脂中間物76(0.2g,0.32mmol)中添加DCM(1mL)及TFA(1mL)。在室溫下振盪混合物20min,且過濾。用DCM/TFA(1:1,3×2mL)洗滌樹脂,真空蒸發合併之濾液。藉由逆相HPLC(ACN/水0.1% TFA,ACN為5%至75%,14min內)純化殘餘物。使純溶離份凍乾,得到呈白色固體狀之(2S,4R)-4-氟基(2-((1R,3R)-1-乙醯氧基-3-((2S,3S)-2-((2R,4R)-1,4-二甲基哌啶-2-甲醯胺基)-N-乙基-3-甲基戊醯胺基)-4-甲基戊基)噻唑-4-甲醯胺基)-5-(4-((S)-6-胺基-2-(6-(2,5-二側氧基-2,5-二氫-1H-吡咯-1-基)己醯胺基)己醯胺基)苯基)-2-甲基戊酸(0.095g,22.48%)。LC-MS:1092[M+1];1H NMR(400MHz,甲醇-d4)δ ppm 7.99(s,1 H),7.34(d,J=8.53Hz,2 H),7.10(d,J=8.53Hz,2 H),6.66(s,2 H),5.64(d,J=10.79Hz,1 H),4.50-4.61(m,1 H),4.21-4.35(m,2 H),3.92(d,J=9.29Hz,1 H),3.69(br.s.,1 H),3.37(t,J=7.15Hz,2 H),3.15-3.35(m,4H),3.04(dt,J=3.58,1.85Hz,1 H),2.84(t,J=7.65Hz,2 H),2.76(d,J=7.03Hz,2 H),2.62(br.s.,2 H),2.38-2.52(m,2 H),2.25(t,J=11.54Hz,1 H),2.16(t,J=7.40Hz,2 H),2.04-2.11(m,4 H),1.70-2.00(m,7 H)1.42-1.69(m,11 H),1.34-1.40(m,1 H),1.27(t,J=6.78Hz,3 H),1.16-1.24(m,2 H),1.01-1.14(m,7 H),0.90(d,J=6.78Hz,3 H),0.94(d,J=6.53Hz,3 H),0.84(t,J=7.40Hz,3 H),0.79(d,J=6.53Hz,3 H)。
向樹脂中間物28中添加(S)-2-((((9H-茀-9-基)甲氧基)羰基)胺基)-5-脲基戊酸(3.88g,9.76mmol)、HATU(3.71g,9.76mmol)、2,4,6-三甲基吡啶(2.59mL,19.52mmol)及DIEA(3.41mL,19.52mmol)於DMF(38mL)中之溶液。在室溫下振盪混合物2小時,過濾所得樹脂,用DMF(3×100mL)、MeOH(3×100mL)及DCM(3×100mL)洗滌,且真空乾燥。自樹脂裂解少量化合物,藉由LCMS分析,其指示反應完成。所得樹脂中間物77用於下一步反應中。LC-MS:1150(M+1)。
向樹脂中間物77中添加20%哌啶於DMF中之溶液(35mL)。在室溫下振盪混合物6分鐘。過濾所得樹脂,用DMF(3×100mL)、MeOH(3×100mL)及DCM(3×100mL)洗滌,且真空乾燥。自樹脂裂解少量化合物,藉由LCMS分析且展示弱信號。所得樹脂中間物78用於下一步反應中。LC-MS:928(M+1)。
向樹脂中間物78中添加(S)-2-((((9H-茀-9-基)甲氧基)羰基)胺基)-3-甲基丁酸(1.529g,4.50mmol)、HATU(1.713g,4.50mmol)、2,4,6-三甲基吡啶(1.294mL,9.76mmol)及DIEA(1.705mL,9.76mmol)於DMF(20mL)中之溶液。在室溫下振盪混合物2小時,過濾所得樹脂,用DMF(3×75mL)、MeOH(3×75mL)及DCM(3×75mL)洗滌,且真空乾燥。自樹脂裂解少量化合物,藉由LC/MS分析,其指示反應完成。所得樹脂中間物79用於下一步反應中。LC-MS:1250(M+1)。
向樹脂中間物79中添加20%哌啶於DMF中之溶液(20mL)。在室溫下振盪混合物6分鐘,且過濾所得樹脂,用DMF(3×75mL)、MeOH(3×75mL)及DCM(3×75mL)洗滌,且真空乾燥。自樹脂裂解少量化合物,藉由LCMS分析,其指示反應完成。所得樹脂中間物80用於下一步反應中。LC/MS:1028(M+1)。
在室溫下向樹脂中間物80中依序添加6-(2,5-二側氧基-2,5-二氫-1H-吡咯-1-基)己酸2,5-二側氧基吡咯啶-1-基酯(1.157g,3.75mmol)於DMF(18mL)中之溶液、4-甲基嗎啉(1.032mL,9.38mmol)。在室溫下振盪混合物2小時,且過濾所得樹脂,用DMF(3×75mL)、MeOH(3×75mL)及DCM(3×75mL)洗滌,且真空乾燥。藉由添加TFA裂解少量樹脂且藉由LC/MS分析且指示所需產物形成。樹脂中間物81用於下一步驟中。LC-MS:1220(M+1)。
來自81之向樹脂中添加TFA(2.89mL,37.54mmol)於DCM(40mL)中之溶液。在室溫下振盪混合物5分鐘,過濾所得樹脂,再用50mL DCM洗滌。濃縮合併之萃取物。藉由逆相HPLC(C18管柱,0.1%TFA/水/0.1 TFA乙腈,0至40%,30分鐘方法)純化粗物質。使純溶離份凍乾,得到呈白色固體狀之(2S,4R)-4-氟基(2-((1R,3R)-1-乙醯氧基-3-((2S,3S)-2-((2R,4R)-1,4-二甲基哌啶-2-甲醯胺基)-N-乙基-3-
甲基戊醯胺基)-4-甲基戊基)噻唑-4-甲醯胺基)-5-(4-((S)-2-((S)-2-(6-(2,5-二側氧基-2,5-二氫-1H-吡咯-1-基)己醯胺基)-3-甲基丁醯胺基)-5-脲基戊醯胺基)苯基)-2-甲基戊酸(0.620g,12.38%)。LC-MS:1220(M+1);1H NMR(400MHz,CD3OD)δ ppm 8.03(s,1 H),7.30-7.44(m,2 H),7.07(d,J=8.53Hz,2 H),6.69(s,2 H),5.53-5.68(m,1 H),4.52-4.63(m,1 H),4.19-4.40(m,3 H),4.01-4.12(m,2 H),3.89-3.99(m,1 H),3.56-3.74(m,1 H),3.33-3.43(m,2 H),3.23-3.32(m,1 H),2.96-3.13(m,4 H),2.83-2.95(m,1 H),2.66-2.83(m,3 H),2.57(br.s.,3 H),2.40-2.52(m,2 H),2.14-2.24(m,3 H),2.02-2.11(m,4 H),1.87-2.00(m,5 H),1.72-1.87(m,4 H),1.42-1.68(m,10 H),1.16-1.28(m,5H),1.09(d,J=7.03Hz,6 H,)0.76-0.96(m,16 H)。
向樹脂中間物38(0.35g,0.56mmol)中添加(S)-2-((((9H-茀-9-基)甲氧基)羰基)胺基)-6-((第三丁氧羰基)胺基)己酸(0.525g,1.12mmol)、HATU(0.426g,1.12mmol)、2,4,6-三甲基吡啶(0.223mL,1.68mmol)及DIPEA(0.293mL,1.68mmol)於DMF(5mL)中之溶液。在室溫下振盪混合物2小時,過濾所得樹脂,用DMF(3×5mL)、MeOH(3×5mL)及DCM(3×5mL)洗滌,且真空乾燥。自樹脂裂解少量化合物,藉由LCMS分析,其指示反應完成。所得樹脂中間物82用
於下一步反應中。LC/MS:1221(M+1)。
向樹脂中間物82中添加含20%哌啶之DMF(4mL)。在室溫下振盪混合物6min,且過濾所得樹脂,用DMF(3×5mL)、MeOH(3×5mL)、DCM(3×5mL)洗滌,且真空乾燥。自樹脂裂解少量化合物,藉由LC/MS分析,其指示反應完成。所得樹脂中間物83用於下一步反應中。LC/MS:999(M+1)。
在室溫下向樹脂中間物83中依序添加6-(2,5-二側氧基-2,5-二氫-1H-吡咯-1-基)己酸2,5-二側氧基吡咯啶-1-基酯(0.259g,0.84mmol)於DCM(4mL)中之溶液、4-甲基嗎啉(0.185mL,1.68mmol)。在室溫下振盪混合物6小時,過濾所得樹脂,用DMF(3×5mL)、MeOH(3×5mL)及DCM(3×5mL)洗滌,真空乾燥。自樹脂裂解少量化合物,藉由LC/MS分析,其指示反應完成。所得樹脂中間物84用於下一步反應中。LC-MS:1192(M+1)。
向樹脂中間物84(0.35g,0.56mmol)中添加含TFA(0.216mL,2.80mmol)之DCM(5mL)。在室溫下振盪混合物10分鐘。減壓移除溶劑。將殘餘物溶解於DMSO中,且藉由逆相HPLC(0.1 TFA/水/乙腈,20至80%,14分鐘)純化。使含有純產物之溶離份凍乾,得到呈白色固體狀之(2S,4R)-4-氟基(2-((1R,3R)-1-乙醯氧基-3-((2S,3S)-2-(1,2-二甲基哌啶-2-甲醯胺基)-N-乙基-3-甲基戊醯胺基)-4-甲基戊基)噻唑-4-甲醯胺基)-5-(4-((S)-6-((第三丁氧羰基)胺基)-2-(6-(2,5-二側氧基-2,5-二氫-1H-吡咯-1-基)己醯胺基)己醯胺基)苯基)-2-甲基戊酸(0.123g,18.42%)。LC/MS:1192(M+1)。
向中間物85(95mg,0.08mmol)中添加TFA(0.123mL,1.59mmol)於DCM(1mL)中之溶液。在室溫下振盪混合物1小時。減壓移除溶劑。將殘餘物溶解於DMSO中,且藉由逆相HPLC(0.1 TFA/水/乙腈,10至70%,10分鐘)純化。使含有純產物之溶離份凍乾,得到呈白色固體狀之(2S,4R)-4-氟基(2-((1R,3R)-1-乙醯氧基-3-((2S,3S)-2-((R)-1,2-二甲基哌啶-2-甲醯胺基)-N-乙基-3-甲基戊醯胺基)-4-甲基戊基)噻唑-4-甲醯胺基)-5-(4-((S)-6-胺基-2-(6-(2,5-二側氧基-2,5-二氫-1H-吡咯-1-基)己醯胺基)己醯胺基)苯基)-2-甲基戊酸(53.0mg,50.4%)。LC-MS:1092(M+1);1H NMR(400MHz,CD3OD)δ ppm
7.97(s,1 H),7.36(d,J=8.28Hz,2 H),7.11(d,J=8.28Hz,2 H),6.65(s,2 H),5.63(d,J=11.29Hz,1 H),4.34(dd,J=8.28,5.77Hz,1 H),4.26(br.s.,1 H),3.75-3.60(m,1 H),3.32-3.46(m,4 H),3.30-3.25(m,1 H),2.71-2.90(m,5 H),2.49-2.62(m,3 H),2.27(t,J=12.05Hz,1 H),2.17(t,J=7.40Hz,3 H)2.00-2.12(m,5 H),1.84-1.96(m,3 H),1.72-1.84(m,4 H),1.58-1.69(m,5 H),1.47-1.56(m,4 H),1.36-1.44(m,5 H),1.14-1.30(m,6 H),1.01-1.10(m,4 H),0.93(dd,J=13.93,6.65Hz,7 H),0.74-0.86(m,7 H)。
在室溫下向樹脂中間物75(0.20g,0.16mmol)中依序添加2,5-二側氧基吡咯啶-1-基-3-(2,5-二側氧基-2,5-二氫-1H-吡咯-1-基)丙酸酯(85mg,0.32mmol)於DCM中之溶液、DIEA(0.056mL,0.32mmol)。在室溫下振盪混合物4小時,用DMF(3×3mL)、DCM(3×3mL)及MeOH(3×3mL)洗滌所得樹脂,且真空乾燥。用TFA/DCM(1:2)自樹脂裂解少量化合物。蒸發溶劑之後,藉由LC/MS分析粗產物。LC/MS指示偶合反應完成。LC/MS:1050.37(M+1)。
在室溫下向樹脂中間物86(0.20g,0.16mmol)中添加TFA/DCM(1:2,3mL)。在室溫下振盪混合物10min且過濾。用DCM(3×3mL)洗滌樹脂,合併所有濾液且減壓蒸發,得到粗產物。藉由逆相HPLC(具有0.1% TFA之H2O及CH3CN,CH3CN為5%至40%,長度為12CV)純化粗產物。合併收集之溶離份且凍乾,得到呈白色粉末狀之(2S,4R)-4-氟基(2-((1R,3R)-1-乙醯氧基-3-((2S,3S)-2-((2R,4R)-1,4-二甲基哌啶-2-甲醯胺基)-N-乙基-3-甲基戊醯胺基)-4-甲基戊基)噻唑-4-甲醯胺基)-5-(4-((S)-6-胺基-2-(3-(2,5-二側氧基-2,5-二氫-1H-吡咯-1-基)丙醯胺基)己醯胺基)苯基)-2-甲基戊酸(70mg,35%)。LC/MS:1050.37(M+1);1H NMR(400MHz,甲醇-d 4)δ 7.99(s,1H),7.35(d,J=8.5Hz,2H),7.10(d,J=8.5Hz,2H),6.65(s,2H),5.64(d,J=10.9Hz,1H),4.56(d,J=8.9Hz,1H),4.28(td,J=11.3,10.0,6.1Hz,2H),3.92(d,J=11.5Hz,1H),3.69(q,J=6.8Hz,3H),3.31-3.23(m,1H),3.18(s,1H),2.83(t,J=7.7Hz,3H),2.76(d,J=7.1Hz,3H),2.63(s,3H),2.50-2.40(m,4H),2.25(t,J=12.8Hz,1H),2.06(s,4H),2.00-1.69(m,8H),1.69-1.52(m,6H),1.53-1.31(m,4H),1.28(d,J=6.4Hz,3H),1.08(d,J=7.1Hz,7H),0.92(dd,J=13.7,6.7Hz,7H),0.83(t,J=7.4Hz,4H),0.78(d,J=6.6Hz,3H)。
含有抗體之ADC可藉由標準方法,諸如(但不限於)醛/希夫鍵聯、硫氫基鍵聯、酸不穩定鍵聯、順式烏頭醯基鍵聯、腙鍵聯,藉由類似於藉由Hamblett,Clin.Cancer Res.2004,10,7063-7070;Doronina等人,Nat.Biotechnol.2003,21(7),778-784及Francisco等人,Blood,2003,102,1458-1465所述之方法及以下非限制性實例之適當改變來製備。
藉由在37℃下在還原條件下使用含40莫耳當量TCEP之PBS(pH 7.2)及1mM EDTA處理抗體3小時,以移除硫醇反應性物質,諸如半胱胺酸、麩胱甘肽、金屬且還原抗體中之鏈間二硫鍵。此步驟繼之以在4℃下於PBS(pH 7.2)、1mM EDTA中使用10,000 MWCO透析盒(Thermo Scientific)之兩輪透析。在25℃下於PBS(pH 7.2)、1mM EDTA中藉由用去氫抗壞血酸氧化4小時在抗體之上重新形成二硫鍵。其後,20莫耳當量之式II化合物經由抗體之反應性巰基藉由在25℃下於PBS(pH 7.2)、1mM EDTA,10% v/v DMSO(二甲亞碸)(Thermo Scientific)中培育1小時結合。藉由過濾純化結合物。藉由添加4莫耳當量之N-乙醯基半胱胺酸(Sigma-Aldrich)猝滅結合反應物。在4℃下使用20K MWCO卡匣在5mM NaPO4(pH 6)中透析抗體-藥物結合物隔夜,且隨後使用5mL II型陶瓷羥基磷灰石(CHT)管(Biorad)純化。結合物使用10mM NaPO4(pH 6)及0至2M NaCl線性梯度自管溶離且可濃縮且藉由緩衝劑交換於20mM組胺酸-HCl(pH 6.0)中透析來調配。
獲自美國典型組織收集中心(American Type Tissue Collection,ATCC)(P.O.Box 1549,Manassa,VA 20108(USA))之一組人類癌細胞株(DU 145、NCI-N87及MDA至MB-361)用以測定本發明妥布賴森化合物之相對細胞毒性。將細胞於培養基中以2,000至5,000個/孔之密度
以80μl之體積接種於組織培養物處理之96孔板中,且使得黏著隔夜。各所測試化合物之5倍濃縮物藉由用培養基稀釋測試物品來製備。將20微升各測試物品一式兩份或一式三份添加至細胞中,使得以逐步1:4連續稀釋,最終劑量曲線在4μg/ml至61pg/ml範圍內。在37℃/5% CO2下培養經處理之細胞72至144小時。使用來自Promega之CellTiter-Glo發光存活率分析來測定相對細胞毒性。簡言之,將100μl CellTiter-Glo試劑添加至各孔中,使得在室溫下在輕度振盪下培育10分鐘,接著使用Perkin Elmer EnVision光度計讀取560nM下各樣品之吸收。細胞存活率百分比藉由下式計算:(處理之樣品之平均發光/對照(未處理)樣品之平均發光)×100。IC50值用GraphPad Prism軟體使用對數非線性回歸分析來測定。並非所有化合物均針對所有細胞株進行分析。表I提供分析資料。
本文中所引用之全部參考文獻(包括專利、專利申請案、論文、課本及其類似者)及其中引用之參考文獻在其尚未引用之程度上,在此以全文引用之方式併入本文中,達成所有目的。
Claims (39)
- 一種化合物,其具有式I之結構:
- 如請求項1之化合物,其中n為1且R1為甲基。
- 如請求項1之化合物,其中R2為甲基。
- 如請求項1之化合物,其中R3為NH2。
- 如請求項1之化合物,其中n為1,R1為甲基,R2為甲基且R3為NH2。
- 一種式(Ii)化合物,
- 一種式(Iii)化合物,
- 一種式(Iiii)化合物,
- 一種式(Iiv)化合物,
- 一種式(Iv)化合物,
- 一種式(Ivi)化合物,
- 一種化合物,其具有式II之結構:
- 如請求項12之化合物,其中n為1且R1為甲基。
- 如請求項12之化合物,其中R2為甲基。
- 如請求項12之化合物,其中R3為NH2。
- 如請求項12之化合物,其中n為1,R1為甲基,R2為甲基且R3為NH2。
- 如請求項12之化合物,其中R4為(CH2)4NH2。
- 如請求項12之化合物,其中R5為H。
- 如請求項12之化合物,其中R6為CH2。
- 如請求項12之化合物,其中m為1。
- 如請求項12之化合物,其中n為1,m為1,R1為甲基,R2為甲 基,R3為NH2,R4為(CH2)4NH2,R5為H且R6為CH2。
- 一種式(IIi)化合物,
- 一種式(IIii)化合物,
- 一種式(IIiii)化合物,
- 一種式(IIiv)化合物,
- 一種抗體-藥物結合物,其為具有式II結構之化合物
- 如請求項26之抗體-藥物結合物,其中該抗體為單株抗體。
- 如請求項26之抗體-藥物結合物,其中該抗體對癌症抗原具有特異性。
- 如請求項26之抗體-藥物結合物,其中該抗體為阿侖單抗、貝伐單抗、貝倫妥單抗、西妥昔單抗、吉妥珠單抗、伊派利單抗、奧伐木單抗、帕尼單抗、利妥昔單抗、托西莫單抗或曲妥珠單抗。
- 一種抗體-藥物結合物,其為式(IIi)化合物 及抗體之結合物。
- 一種抗體-藥物結合物,其為式(IIii)化合物
- 一種抗體-藥物結合物,其為式(IIiii)化合物
- 一種抗體-藥物結合物,其為式(IIiv)化合物之結合物
- 一種醫藥組合物,其含有如請求項1至25中任一項之化合物。
- 一種醫藥組合物,其含有如請求項26至33中任一項之抗體-藥物結合物。
- 一種治療癌症之方法,其藉由向患有癌症之個體投與有效量之如請求項1至25中任一項之化合物實現。
- 如請求項36之方法,其中該個體患有鱗狀細胞癌、小細胞肺癌、非小細胞肺癌、腸胃癌、霍奇金氏淋巴瘤(Hodgkin's lymphoma)、非霍奇金氏淋巴瘤、胰臟癌、神經膠母細胞瘤、神經膠質瘤、子宮頸癌、卵巢癌、肝癌、膀胱癌、乳癌、結腸癌、結腸直腸癌、子宮內膜癌、骨髓瘤、唾液腺癌、腎癌、基底細胞癌、黑色素瘤、前列腺癌、陰門癌、甲狀腺癌、睾丸癌、食道癌、頭頸癌、黏液性卵巢癌、膽管癌或乳頭狀腎癌。
- 一種治療癌症之方法,其藉由向患有癌症之個體投與有效量之如請求項26至33中任一項之抗體-藥物結合物實現。
- 如請求項38之方法,其中該個體患有鱗狀細胞癌、小細胞肺癌、非小細胞肺癌、腸胃癌、霍奇金氏淋巴瘤、非霍奇金氏淋巴瘤、胰臟癌、神經膠母細胞瘤、神經膠質瘤、子宮頸癌、卵巢癌、肝癌、膀胱癌、乳癌、結腸癌、結腸直腸癌、子宮內膜癌、骨髓瘤、唾液腺癌、腎癌、基底細胞癌、黑色素瘤、前列 腺癌、陰門癌、甲狀腺癌、睾丸癌、食道癌、頭頸癌、黏液性卵巢癌、膽管癌或乳頭狀腎癌。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461978460P | 2014-04-11 | 2014-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201625662A true TW201625662A (zh) | 2016-07-16 |
Family
ID=54264545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW104111700A TW201625662A (zh) | 2014-04-11 | 2015-04-10 | 妥布賴森(tubulysin)衍生物 |
Country Status (19)
Country | Link |
---|---|
US (2) | US9427479B2 (zh) |
EP (1) | EP3129362A4 (zh) |
JP (1) | JP2017510661A (zh) |
KR (1) | KR20160142392A (zh) |
CN (1) | CN106458942A (zh) |
AR (1) | AR100006A1 (zh) |
AU (1) | AU2015243379B2 (zh) |
CA (1) | CA2945318A1 (zh) |
CL (1) | CL2016002548A1 (zh) |
EA (1) | EA032203B1 (zh) |
IL (1) | IL247822A0 (zh) |
MA (1) | MA39862A (zh) |
MX (1) | MX2016013373A (zh) |
NZ (1) | NZ725131A (zh) |
PH (1) | PH12016501995A1 (zh) |
SG (1) | SG11201608203RA (zh) |
TW (1) | TW201625662A (zh) |
UY (1) | UY36075A (zh) |
WO (1) | WO2015157594A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI753252B (zh) * | 2019-05-03 | 2022-01-21 | 中國大陸商杭州多禧生物科技有限公司 | 含支鏈連接體的Tubulysin同系物偶聯物 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201625662A (zh) * | 2014-04-11 | 2016-07-16 | 麥迪紐有限責任公司 | 妥布賴森(tubulysin)衍生物 |
EP3129055B1 (en) | 2014-04-11 | 2020-07-01 | MedImmune, LLC | Bispecific her2 antibodies |
EA201791896A1 (ru) * | 2015-02-25 | 2018-02-28 | Уильям Марш Райс Юниверсити | Дезацетокситубулизин н и его аналоги |
DK3374398T3 (da) | 2015-11-10 | 2020-06-08 | Medimmune Llc | Bindingsmolekyler, som er specifikke for asct2, og anvendelser deraf |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
CA3006000A1 (en) | 2015-12-04 | 2017-06-08 | Seattle Genetics, Inc. | Conjugates of quaternized tubulysin compounds |
US10723727B2 (en) * | 2016-02-01 | 2020-07-28 | Pfizer Inc. | Tubulysin analogs and methods for their preparation |
EP3442574A4 (en) | 2016-04-15 | 2019-12-11 | MacroGenics, Inc. | NOVEL B7-H3 BINDING MOLECULES, THEIR ANTIBODY-MEDICINAL CONJUGATES AND METHODS OF USE |
EP3525829A1 (en) | 2016-10-11 | 2019-08-21 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
EP3661963A1 (en) | 2017-08-01 | 2020-06-10 | MedImmune, LLC | Bcma monoclonal antibody-drug conjugate |
MX2020006192A (es) * | 2017-12-31 | 2020-08-20 | Hangzhou Dac Biotech Co Ltd | Un conjugado de un analogo de tubulisina con enlazadores ramificados. |
CN109456212A (zh) * | 2018-12-03 | 2019-03-12 | 康化(上海)新药研发有限公司 | 一种沙库比曲中间体的合成方法 |
EP3986463A4 (en) * | 2019-06-24 | 2023-03-15 | Hangzhou Dac Biotech Co., Ltd. | CYTOTOXIC AGENT-CELL-BINDING MOLECULE CONJUGATE WITH BRANCHED LINKERS |
WO2021262910A2 (en) * | 2020-06-24 | 2021-12-30 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
WO2022053650A1 (en) | 2020-09-11 | 2022-03-17 | Medimmune Limited | Therapeutic b7-h4 binding molecules |
CA3237211A1 (en) | 2021-11-10 | 2023-05-19 | Astrazeneca Ab | Antibody molecules and conjugates |
GB202117928D0 (en) | 2021-12-11 | 2022-01-26 | Cancer Research Tech Ltd | Immunotherapy for cancer |
WO2024002938A1 (en) | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7064211B2 (en) * | 2002-03-22 | 2006-06-20 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof |
US20060148014A1 (en) * | 2004-12-09 | 2006-07-06 | Sergei Agoulnik | Tubulin isotype screening in cancer therapy using hemiasterlin analogs |
IT1394860B1 (it) * | 2009-07-22 | 2012-07-20 | Kemotech S R L | Composti farmaceutici |
US8394922B2 (en) * | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
RU2586885C2 (ru) * | 2011-11-17 | 2016-06-10 | Пфайзер Инк. | Цитотоксические пептиды и их конъюгаты антитело-лекарственное средство |
KR20140139480A (ko) * | 2011-12-05 | 2014-12-05 | 이제니카 바이오테라퓨틱스, 인크. | 항체-약물 접합체 및 관련 화합물, 조성물, 및 방법 |
MX356698B (es) * | 2013-02-14 | 2018-06-11 | Bristol Myers Squibb Co | Compuestos de tubulisina, metodos para obtenerlos y uso. |
WO2015155345A1 (en) | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
TW201625662A (zh) * | 2014-04-11 | 2016-07-16 | 麥迪紐有限責任公司 | 妥布賴森(tubulysin)衍生物 |
EP3129055B1 (en) * | 2014-04-11 | 2020-07-01 | MedImmune, LLC | Bispecific her2 antibodies |
-
2015
- 2015-04-10 TW TW104111700A patent/TW201625662A/zh unknown
- 2015-04-10 EP EP15777523.0A patent/EP3129362A4/en not_active Withdrawn
- 2015-04-10 WO PCT/US2015/025235 patent/WO2015157594A1/en active Application Filing
- 2015-04-10 UY UY0001036075A patent/UY36075A/es not_active Application Discontinuation
- 2015-04-10 SG SG11201608203RA patent/SG11201608203RA/en unknown
- 2015-04-10 MA MA039862A patent/MA39862A/fr unknown
- 2015-04-10 AR ARP150101089A patent/AR100006A1/es unknown
- 2015-04-10 KR KR1020167031176A patent/KR20160142392A/ko unknown
- 2015-04-10 MX MX2016013373A patent/MX2016013373A/es unknown
- 2015-04-10 JP JP2017504616A patent/JP2017510661A/ja active Pending
- 2015-04-10 CA CA2945318A patent/CA2945318A1/en not_active Abandoned
- 2015-04-10 NZ NZ725131A patent/NZ725131A/en not_active IP Right Cessation
- 2015-04-10 US US14/683,196 patent/US9427479B2/en not_active Expired - Fee Related
- 2015-04-10 CN CN201580031041.XA patent/CN106458942A/zh active Pending
- 2015-04-10 EA EA201691963A patent/EA032203B1/ru not_active IP Right Cessation
- 2015-04-10 AU AU2015243379A patent/AU2015243379B2/en not_active Ceased
-
2016
- 2016-08-08 US US15/230,918 patent/US10159745B2/en not_active Expired - Fee Related
- 2016-09-14 IL IL247822A patent/IL247822A0/en unknown
- 2016-10-06 CL CL2016002548A patent/CL2016002548A1/es unknown
- 2016-10-07 PH PH12016501995A patent/PH12016501995A1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI753252B (zh) * | 2019-05-03 | 2022-01-21 | 中國大陸商杭州多禧生物科技有限公司 | 含支鏈連接體的Tubulysin同系物偶聯物 |
Also Published As
Publication number | Publication date |
---|---|
CA2945318A1 (en) | 2015-10-15 |
EA032203B1 (ru) | 2019-04-30 |
WO2015157594A1 (en) | 2015-10-15 |
AU2015243379B2 (en) | 2018-02-01 |
EA201691963A1 (ru) | 2017-06-30 |
SG11201608203RA (en) | 2016-10-28 |
MA39862A (fr) | 2017-02-15 |
CN106458942A (zh) | 2017-02-22 |
US20150291657A1 (en) | 2015-10-15 |
PH12016501995A1 (en) | 2017-01-09 |
UY36075A (es) | 2015-10-30 |
CL2016002548A1 (es) | 2017-02-24 |
NZ725131A (en) | 2018-03-23 |
US20160339114A1 (en) | 2016-11-24 |
JP2017510661A (ja) | 2017-04-13 |
AU2015243379A1 (en) | 2016-11-03 |
US10159745B2 (en) | 2018-12-25 |
IL247822A0 (en) | 2016-11-30 |
KR20160142392A (ko) | 2016-12-12 |
AR100006A1 (es) | 2016-08-31 |
MX2016013373A (es) | 2017-05-02 |
EP3129362A1 (en) | 2017-02-15 |
US9427479B2 (en) | 2016-08-30 |
EP3129362A4 (en) | 2017-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201625662A (zh) | 妥布賴森(tubulysin)衍生物 | |
JP7467557B2 (ja) | 抗her2抗体-薬物コンジュゲート | |
TWI820044B (zh) | 抗體-吡咯并苯二氮呯衍生物複合體 | |
TWI762487B (zh) | 抗-b7-h3抗體及抗體藥物結合物 | |
US11185594B2 (en) | (Anti-HER2 antibody)-drug conjugate | |
EP3468996B1 (en) | Anti-egfr antibody drug conjugates | |
CN111565750B (zh) | 抗tm4sf1抗体及其使用方法 | |
TW202102228A (zh) | 抗體-吡咯并苯二氮呯衍生物結合物 | |
EP3888689A1 (en) | Anti-egfr antibody drug conjugates | |
KR20230038738A (ko) | 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도 | |
WO2021195598A2 (en) | Degrader-antibody conjugates and methods of using same | |
EP4188449A2 (en) | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same | |
CN114652853A (zh) | 抗il-4r抗体-药物偶联物及医药用途 | |
WO2021222783A1 (en) | Anti-tm4sf1 antibody drug conjugates and methods of using same | |
AU2022245388A1 (en) | Maytansine-antibody conjugates and methods of using same | |
EP4204013A1 (en) | Antimitotic tetrapeptide-antibody conjugates and methods of using same | |
WO2023239803A1 (en) | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same | |
WO2023056069A1 (en) | Degrader-antibody conjugates and methods of using same | |
NZ788873A (en) | Anti-B7-H3 antibodies and antibody drug conjugates |